Definition
The leucokinins are small insect neuropeptides which were originally isolated from head extracts of the Madeira cockroach, Leucophaea maderae. They stimulate the contractions of the cockroach's lower digestive tract.
Discovery
Identification of leucokinins and their cognate receptors has been successfully undertaken in cockroach, Leucophaea maderae, including the genetically tractable Dipteran, Drosophila Melanogaster, progress has been made in studies of leucokinin signalling in biomedically relevant insects.1, 2, 3.
Structural Characteristics
I and III are flanked by dibasic proteolytic cleavage sites, and in all three peptides a C-terminal Gly is present, which is predicted to be processed into a C-terminal amide group in the mature peptides. A different proteolytic cleavage site is present at the N terminus of leucokinin II, consisting of a single Arg with a Lys at residue –8. Four Cys residues are also present in the protein region before to the leucokinin peptide sequences. The position of the four Cys residues is identical, suggesting that these residues may play an important role in the function of the precursor protein, perhaps in the formation of disulphide bridges. It has been proposed that these residues are responsible for paraldehyde 4.
Mode of Action
in the cockroach increase motility of the isolated hindgut. Surprisingly, synthetic leucokinins have biological activity in a different insect and in a different tissue. In isolated Malpighian tubules of the yellow fever mosquito Aedes aegypti, leucokinins depolarize the transepithelial voltage. This effect on voltage is dependent on extracellular Cl. One leucokinin, LK-8, the effects of which were studied further in isolated Malpighian tubules, was found to inhibit transepithelial fluid secretion at low concentrations and to stimulate fluid secretion at high concentrations. The depolarizing effects on voltage and the stimulation of fluid secretion suggest that leucokinins increase the Cl permeability of the tubule wall thereby increasing the availability of Cl for secretion with Na, K and water. Structure-function comparisons of the seven leucokinins studied suggest that the active region of the octapeptide is segregated to the C-terminal pentapeptide. In view of the known effects of leucokinins on hindgut motility in the cockroach, finding of effects in mosquito Malpighian tubules suggests that leucokinins may be widely distributed in insects where they may have diverse functions in a variety of organs 5.
Functions
act on the leucokinin receptor to raise intracellular calcium having identified both leucokinins and a leucokinin-like receptor within Anopheles, it was established that they are a functional receptor–ligand pairing. The action of leucokinins on tubules were consistent with the existence of more than one receptor and that the broad concentration range of Drosophila leucokinin on Drosophila tubule was also taken as suggestive of multiple receptor classes.
Cross-specific leucokinin signaling, the effects of the Anopheles leucokinins on S2 cells expressing the Drosophila LKR, CG10626 were also established. Drosophila leucokinin was found to stimulate the A. stephensi receptor in a similar manner to the Anopheles leucokinins, displaying an EC50 value of 1.1•nmol, very similar to that of Anopheles leucokinin I.
Drosophila leucokinin was also found to activate the Anopheles receptor with a similar EC50 value to Anopheles leucokinin I. However, when the Anopheles peptides were applied to the Drosophila receptor, only Anopheles leucokinin I and II elicited a rise in Ca2+. This suggests that the Anopheles receptor has a broader specificity for leucokinin ligands than the Drosophila receptor 6. The insect leucokinins have attracted a great deal of interest as lead molecules for novel pesticides, including the development of peptidase resistant analogues of this family of peptides. Insect leucokinins have diverse roles; they act via their cognate G protein-coupled receptors (GPCRs). Furthermore, as leucokinins have only been found in invertebrates, it is likely that careful design of leucokinin antagonist or agonist analogues will avoid interactions with mammalian species. Recent studies have suggested the involvement of leucokinins in dietary regulation and energy mobilisation 6.
References
1. Holman GM, Cook BJ, Wagner RM (1984). Isolation and partial characterization of five myotropic peptides present in head extracts of the cockroach, Leucophaea maderae. Comp. Biochem. Physiol., 77(1):1-5.
2. Holman GM, Nachman RJ Coast GM (1999). Isolation, characterization and biological activity of a diuretic myokinin neuropeptide from the housefly, Musca domestica. Peptides, 20:1-10.
3. Terhzaz S, O’Connell FC, Pollock, VP, Kean L, Davies SA, Veenstra, JA, Dow, JAT (1999). Isolation and characterization of a leucokinin-like peptide of Drosophila melanogaster. J Exp Biol., 202:3667-3676.
4. Veenstra JA, Pattillo JM, Petzel DH (1997). A single cDNA encodes all three Aedes leucokinins, which stimulate both fluid secretion by the Malpighian tubules and hindgut contractions. J. Biol. Chem., 272:10402- 10407.
5. Hayes TK, Pannabecker TL, Hinckley DJ, Holman GM, Nachman RJ, Petzel DH, Beyenbach KW (1989). , a new family of ion transport stimulators and inhibitors in insect Malpighian tubules. Life Sci., 44(18):1259-1266.
6. Radford JC, Terhzaz S, Cabrero P, Davies SA, Dow JA (2004). Functional characterisation of the Anopheles leucokinins and their cognate G-protein coupled receptor. The Journal of Experimental Biology, 207
Saturday, October 31, 2009
Leptin and Fragments
Definition
Leptin is a 16 kDa protein hormone originally discovered in adipose tissue where it acts as a satiety factor in signalling whole body energy balance.
Discovery
In 1950, at Jackson Lab the effects of leptin were observed while studying obese mice with random mutation 1. The obese yellow mice were attaining weights up to 75 or 80 grams. Later leptin was discovered in 1994 by Jeffrey M. Friedman et al., through the study of such mice. Mutation of ob (obese gene) resulted in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans 2.
Structural Characteristics
Leptin of humans has 146 amino acid sequence containing one disulphide bond. Its molecular weight is around 16 kDa. Leptin has 67% sequence identity among diverse species. Leptin is a four-helix bundle with one very short strand segment and two relatively long interconnected loops. This is consistent with a classification as a cytokine four-helix bundle 3.
Mode of Action
Leptin acts via specific receptors (Ob-R), of which six isoforms are at present recognized (from Ob-Ra to Ob-Rf). Ob-Rb is the only isoform able to activate JAK-STAT and MAPK signaling cascades. A large body of evidence suggests that leptin and its receptors are involved in prostate physiology and pathophysiology in humans. Ob-R in rat is involved in the autocrine-paracrine functional regulation of the epithelial cells of adult rat seminal vesicles and prostate 4. Once leptin has bound to the Ob-Rb receptor, it activates the stat3, which is phosphorylated and travels to the nucleus to, presumably, effect changes in gene expression. One of the main effects on gene expression is the down-regulation of the expression of endocannabinoids, responsible for increasing appetite. In response to leptin, receptor neurons have been shown to remodel themselves, changing the number and types of synapses that fire onto them. Mutation of ob results in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans. The ob gene product may function as part of a signalling pathway from adipose tissue that acts to regulate the size of the body fat depot 5.
Functions
Adiposity signal, Leptin is an adiposity hormone that modulates the activity of multiple hypothalamic signaling pathways involved in the control of food intake. Administration of leptin or one of its downstream mediators, neuropeptide Y (NPY), could affect food intake by modulating the brain stem neurophysiological response to ascending meal-related feedback signals in the nucleus of the solitary tract (NTS) in anesthetized male Long-Evans rats 6.
Appetite control, leptin binds to NPY neurons in the arculate nucleus, in such a way that decreases the activity of these neurons. Leptin signals to the brain that the body has had enough to eat, or satiety. A very small group of humans possess homozygous mutations for the leptin gene which leads to a constant desire for food, resulting in severe obesity.
Modulation of T cell activity, the role of Leptin/Leptin receptors in modulation of T cell activity in immune system was shown in experimentation with mice. Leptin/leptin receptor pathway is involved in the modulation of the regulatory immune response in atherosclerosis, and alteration in regulatory immunity may predispose obese individuals to atherosclerosis 7.
Lung surfactant activity, in fetal lung leptin is induced in the alveolar interstitial fibroblasts ("lipofibroblasts") by the action of PTHrP secreted by formative alveolar epithelium (endoderm) under moderate stretch. The leptin from the mesenchyme in turn acts back on the epithelium at the leptin receptor carried in the alveolar type II pneumocytes and induces surfactant expression which is one of the main functions of these type II pneumocytes 8.
Reproduction, it appears that leptin and estradiol interact coordinately in a concentration-dependent manner to control IVF outcome. In mice, leptin is also required for male and female fertility. In mammals, ovulatory cycles in females are linked to energy balance (positive or negative depending on whether a female is losing or gaining weight) and energy flux (how much energy is consumed and expended) much more than energy status (fat levels) 9.
References
1. Ingalls AM, Dickie MM, Snell GD (1950). Obese, a new mutation in the house mouse. J. Hered., 41(12):317-318.
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994). Positional cloning of the mouse obese gene and its human homologue. Nature, 372(6505):425–432.
3. Zhang F, Basinski MB, Beals JM, Briggs SL, Churgay LM, Clawson DK, DiMarchi RD, Furman TC, Hale JE, Hsiung HM, Schoner BE, Smith DP, Zhang XY, Wery JP, Schevitz RW (1997). Crystal structure of the obese protein leptin-E100. Nature, 387:206-209..
4. Malendowicz W, Rucinski M, Macchi C, Spinazzi R, Ziolkowska A, Nussdorfer GG, Kwias Z (2006). Leptin and leptin receptors in the prostate and seminal vesicles of the adult rat. Int. J. Mol. Med., 18(4):615–618.
5. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994). Positional cloning of the mouse obese gene and its human homologue. Nature, 372(6505):425–432.
6. Williams KW, Scott MM, Elmquist JK (2009). From observation to experimentation: leptin action in the mediobasal hypothalamus. Am. J. Clin. Nutr., 89(3):985–990.
7. Taleb S, Herbin O, Ait-Oufella H, Verreth W, Gourdy P, Barateau V, Merval R, Esposito B, Clément K, Holvoet P, Tedgui A, Mallat Z (2007). Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis.. Arterioscler Thromb Vasc Biol., 27(12):2691–2698.
8. Torday JS, Rehan VK (2006). Up-regulation of fetal rat lung parathyroid hormone-related protein gene regulatory network down-regulates the Sonic Hedgehog/Wnt/betacatenin gene regulatory network. Pediatr Res., 60(4):382–388.
9. Anifandis G, Koutselini E, Louridas K, Liakopoulos V, Leivaditis K, Mantzavinos T, Sioutopoulou D, Vamvakopoulos N (2005). Estradiol and leptin as conditional prognostic IVF markers. Reproduction, 129(4):531–534.
Leptin is a 16 kDa protein hormone originally discovered in adipose tissue where it acts as a satiety factor in signalling whole body energy balance.
Discovery
In 1950, at Jackson Lab the effects of leptin were observed while studying obese mice with random mutation 1. The obese yellow mice were attaining weights up to 75 or 80 grams. Later leptin was discovered in 1994 by Jeffrey M. Friedman et al., through the study of such mice. Mutation of ob (obese gene) resulted in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans 2.
Structural Characteristics
Leptin of humans has 146 amino acid sequence containing one disulphide bond. Its molecular weight is around 16 kDa. Leptin has 67% sequence identity among diverse species. Leptin is a four-helix bundle with one very short strand segment and two relatively long interconnected loops. This is consistent with a classification as a cytokine four-helix bundle 3.
Mode of Action
Leptin acts via specific receptors (Ob-R), of which six isoforms are at present recognized (from Ob-Ra to Ob-Rf). Ob-Rb is the only isoform able to activate JAK-STAT and MAPK signaling cascades. A large body of evidence suggests that leptin and its receptors are involved in prostate physiology and pathophysiology in humans. Ob-R in rat is involved in the autocrine-paracrine functional regulation of the epithelial cells of adult rat seminal vesicles and prostate 4. Once leptin has bound to the Ob-Rb receptor, it activates the stat3, which is phosphorylated and travels to the nucleus to, presumably, effect changes in gene expression. One of the main effects on gene expression is the down-regulation of the expression of endocannabinoids, responsible for increasing appetite. In response to leptin, receptor neurons have been shown to remodel themselves, changing the number and types of synapses that fire onto them. Mutation of ob results in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans. The ob gene product may function as part of a signalling pathway from adipose tissue that acts to regulate the size of the body fat depot 5.
Functions
Adiposity signal, Leptin is an adiposity hormone that modulates the activity of multiple hypothalamic signaling pathways involved in the control of food intake. Administration of leptin or one of its downstream mediators, neuropeptide Y (NPY), could affect food intake by modulating the brain stem neurophysiological response to ascending meal-related feedback signals in the nucleus of the solitary tract (NTS) in anesthetized male Long-Evans rats 6.
Appetite control, leptin binds to NPY neurons in the arculate nucleus, in such a way that decreases the activity of these neurons. Leptin signals to the brain that the body has had enough to eat, or satiety. A very small group of humans possess homozygous mutations for the leptin gene which leads to a constant desire for food, resulting in severe obesity.
Modulation of T cell activity, the role of Leptin/Leptin receptors in modulation of T cell activity in immune system was shown in experimentation with mice. Leptin/leptin receptor pathway is involved in the modulation of the regulatory immune response in atherosclerosis, and alteration in regulatory immunity may predispose obese individuals to atherosclerosis 7.
Lung surfactant activity, in fetal lung leptin is induced in the alveolar interstitial fibroblasts ("lipofibroblasts") by the action of PTHrP secreted by formative alveolar epithelium (endoderm) under moderate stretch. The leptin from the mesenchyme in turn acts back on the epithelium at the leptin receptor carried in the alveolar type II pneumocytes and induces surfactant expression which is one of the main functions of these type II pneumocytes 8.
Reproduction, it appears that leptin and estradiol interact coordinately in a concentration-dependent manner to control IVF outcome. In mice, leptin is also required for male and female fertility. In mammals, ovulatory cycles in females are linked to energy balance (positive or negative depending on whether a female is losing or gaining weight) and energy flux (how much energy is consumed and expended) much more than energy status (fat levels) 9.
References
1. Ingalls AM, Dickie MM, Snell GD (1950). Obese, a new mutation in the house mouse. J. Hered., 41(12):317-318.
2. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994). Positional cloning of the mouse obese gene and its human homologue. Nature, 372(6505):425–432.
3. Zhang F, Basinski MB, Beals JM, Briggs SL, Churgay LM, Clawson DK, DiMarchi RD, Furman TC, Hale JE, Hsiung HM, Schoner BE, Smith DP, Zhang XY, Wery JP, Schevitz RW (1997). Crystal structure of the obese protein leptin-E100. Nature, 387:206-209..
4. Malendowicz W, Rucinski M, Macchi C, Spinazzi R, Ziolkowska A, Nussdorfer GG, Kwias Z (2006). Leptin and leptin receptors in the prostate and seminal vesicles of the adult rat. Int. J. Mol. Med., 18(4):615–618.
5. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994). Positional cloning of the mouse obese gene and its human homologue. Nature, 372(6505):425–432.
6. Williams KW, Scott MM, Elmquist JK (2009). From observation to experimentation: leptin action in the mediobasal hypothalamus. Am. J. Clin. Nutr., 89(3):985–990.
7. Taleb S, Herbin O, Ait-Oufella H, Verreth W, Gourdy P, Barateau V, Merval R, Esposito B, Clément K, Holvoet P, Tedgui A, Mallat Z (2007). Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis.. Arterioscler Thromb Vasc Biol., 27(12):2691–2698.
8. Torday JS, Rehan VK (2006). Up-regulation of fetal rat lung parathyroid hormone-related protein gene regulatory network down-regulates the Sonic Hedgehog/Wnt/betacatenin gene regulatory network. Pediatr Res., 60(4):382–388.
9. Anifandis G, Koutselini E, Louridas K, Liakopoulos V, Leivaditis K, Mantzavinos T, Sioutopoulou D, Vamvakopoulos N (2005). Estradiol and leptin as conditional prognostic IVF markers. Reproduction, 129(4):531–534.
Laminin Fragments
Definition
Laminins are the main constituents of basement membranes. These are heterotrimeric glycoproteins composed of a, ß and ? chains held together by disulfide bonds.
Discovery
Laminins were initially discovered by Timpl and Martin in 1979, from a murine fibrosarcoma 1. Laminins play important roles in cell adhesion, proliferation and differentiation and more than eleven LM chains and eleven LM isoforms have already been identified 2, 3. In the developing lung, mRNA for LM chains a1, ß1 and ?1 are detected in both epithelial and mesenchymal cells. LM-1 shares ß1 and ?1 chains with LM-2 and ß1 chain is also found in LM-6, LM- 8, and LM-10 3.
Structural Characteristics
Laminins are multidomain heterotrimers composed of a, ß and ? chains. Previously, laminin trimers were numbered with Arabic numerals in the order discovered, that is laminins-1 to -5. Aumailley et al., in 2005 introduced a new identification system for a trimer using three Arabic numerals, based on the alpha, beta and gamma chain numbers. The laminin with the chain composition a5ß? is termed laminin-511. Instead of the older Roman numeral nomenclature and mixed nomenclature, all modules are now called domains. Laminin epidermal growth factor-like (LE) domains are renumbered starting at the N-terminal, to be consistent with general protein nomenclature. Domain IVb of alpha chains is named laminin 4a (L4a), domain IVa of alpha chains is named L4b, domain IV of gamma chains is named L4, and domain IV of beta chains is named laminin four (LF). The two coiled-coil domains I and II are now considered one laminin coiled-coil domain (LCC). The interruption in the coiled-coil of beta chains is named laminin beta-knob (Lbeta) domain. The chain origin of a domain is specified by the chain nomenclature, such as alpha1L4a 4. Fourteen other chain combinations have been identified in vivo. The trimeric proteins form a cross, giving a structure that can bind to other cell membrane and extracellular matrix molecules 5. The three shorter arms are particularly good at binding to other laminin molecules, which allow them to form sheets. The long arm is capable of binding to cells, which helps anchor organized tissue cells to the membrane.
Mode of Action
Laminin is one of the main glycoproteins of the basement membrane and participates in a series of such biological phenomena such as adhesion, migration, cellular differentiation and the maintenance of the cytoskeleton upon its binding to several components of the matrix, such as collagen type IV, heparin sulphate and entacin 6 7. Laminin is thought to be synthesized by hepatocytes and sinusoidal cells. Stellate cells or lipocytes, produce the largest amount of serum laminin. With the development of hepatic cirrhosis, laminin and collagen deposition occurs both along the fibers of septal fibrosis and subendothelial sinusoids or Disse's space. At the latter site, laminin deposition, together with collagen deposition, determine the formation of a true basement membrane along sinusoids. This phenomenon is called capillarization of Disse's space 8. In the presence of Ca2+, some laminins self.assemble into a polymer through the interaction of their three NH2 termini. When lung organotypic cultures are exposed to a proteolytic fragment of laminin-1 that blocks laminin polymerization. This fragment, referred as E4, comprises the outer globular region of laminin chain. Inhibition of laminin polymerization in lung organotypic cultures resulted in impaired basement membrane assembly and failure of epithelial cells to polarize.
Functions
Networks function, laminins bind to cell membranes through integrin receptors and other plasma membrane molecules, such as the dystroglycan glycoprotein complex and Lutheran blood group glycoprotein. These interactions contribute to cell attachment and differentiation, cell shape and movement, maintenance of tissue phenotype, and promotion of tissue survival
Pathology, dysfunctional structure of one particular laminin, laminin-211, is the cause of one form of congenital muscular dystrophy. Malfunctional laminin-521 in the kidney filter causes leakage of protein into the urine and nephrotic syndrome 9.
In cell structure, recent studies have demonstrated that laminins can be used to culture cells, such as pluripotent stem cells, that are difficult to culture on other substrates. Laminin-111 as well as a mixture of laminins 511 and 521 from human placenta have been used10.
In neural development, Laminin-111 is a major substrate along which nerve axons will grow, both in vivo and in vitro. The presence of laminin-1 can influence the growth cone. For example, growth cones are repelled by netrin when grown on laminin-111, but are attracted to netrin when grown on fibronectin.
References
1. Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR (1979). Laminin – a glycoprotein from basement membranes. J Biol Chem., 254(19):9933-9937.
2. Engel. J (1993). Structure and function of laminin. In Molecular and cellular aspects of basement membranes. Academic Press., 43:147-176.
3. Timpi, R. (1996). Macromolecular organization of basement membrane. Opin.Cell Bioi., 8:618-624.
4. Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E, Jones JC, Kleinman HK, Marinkovich MP, Martin GR, Mayer U, Meneguzzi G, Miner JH, Miyazaki K, Patarroyo M, Paulsson M, Quaranta V, Sanes JR, Sasaki T, Sekiguchi K, Sorokin LM, Talts JF, Tryggvason K, Uitto J, Virtanen I, von der Mark K, Wewer UM, Yamada Y, Yurchenco PD (2005). A simplified laminin nomenclature. Matrix Biol., 24 (5):326-332.
5. Haralson MA, John RH (1995). Extracellular matrix: a practical approach. Ithaca, N.Y: IRL Press.
6. Burgeson RE, Chiquet M, Deutzmann R, Ekblom P, Engel J, Kleinman H (1994). A new nomenclature for the laminins. Matrix Biol., 14:209-211.
7. Aumailley M, Smyth N (1998). The role of laminins in basement membrane function. J Anat., 193:1-21.
8. Schaffner F, Poper H (1963). Capillarization of hepatic sinusoids in man. Gastroenterology, 44:239-242.
9. Yurchenko P and Batton BL (2009). Developmental and pathogenic mechanisms of basement membrane assembly. Curr Pharm Des., 15(12):1277-1294.
10. Domogatskaya A, Rodin S, Boutaud A, Tryggvason K (2008). Laminin-511 but not -332, -111, or -411 enables mouse embryonic stem cell self-renewal in vitro. Stem Cells, 26(11):2800-2809.
Laminins are the main constituents of basement membranes. These are heterotrimeric glycoproteins composed of a, ß and ? chains held together by disulfide bonds.
Discovery
Laminins were initially discovered by Timpl and Martin in 1979, from a murine fibrosarcoma 1. Laminins play important roles in cell adhesion, proliferation and differentiation and more than eleven LM chains and eleven LM isoforms have already been identified 2, 3. In the developing lung, mRNA for LM chains a1, ß1 and ?1 are detected in both epithelial and mesenchymal cells. LM-1 shares ß1 and ?1 chains with LM-2 and ß1 chain is also found in LM-6, LM- 8, and LM-10 3.
Structural Characteristics
Laminins are multidomain heterotrimers composed of a, ß and ? chains. Previously, laminin trimers were numbered with Arabic numerals in the order discovered, that is laminins-1 to -5. Aumailley et al., in 2005 introduced a new identification system for a trimer using three Arabic numerals, based on the alpha, beta and gamma chain numbers. The laminin with the chain composition a5ß? is termed laminin-511. Instead of the older Roman numeral nomenclature and mixed nomenclature, all modules are now called domains. Laminin epidermal growth factor-like (LE) domains are renumbered starting at the N-terminal, to be consistent with general protein nomenclature. Domain IVb of alpha chains is named laminin 4a (L4a), domain IVa of alpha chains is named L4b, domain IV of gamma chains is named L4, and domain IV of beta chains is named laminin four (LF). The two coiled-coil domains I and II are now considered one laminin coiled-coil domain (LCC). The interruption in the coiled-coil of beta chains is named laminin beta-knob (Lbeta) domain. The chain origin of a domain is specified by the chain nomenclature, such as alpha1L4a 4. Fourteen other chain combinations have been identified in vivo. The trimeric proteins form a cross, giving a structure that can bind to other cell membrane and extracellular matrix molecules 5. The three shorter arms are particularly good at binding to other laminin molecules, which allow them to form sheets. The long arm is capable of binding to cells, which helps anchor organized tissue cells to the membrane.
Mode of Action
Laminin is one of the main glycoproteins of the basement membrane and participates in a series of such biological phenomena such as adhesion, migration, cellular differentiation and the maintenance of the cytoskeleton upon its binding to several components of the matrix, such as collagen type IV, heparin sulphate and entacin 6 7. Laminin is thought to be synthesized by hepatocytes and sinusoidal cells. Stellate cells or lipocytes, produce the largest amount of serum laminin. With the development of hepatic cirrhosis, laminin and collagen deposition occurs both along the fibers of septal fibrosis and subendothelial sinusoids or Disse's space. At the latter site, laminin deposition, together with collagen deposition, determine the formation of a true basement membrane along sinusoids. This phenomenon is called capillarization of Disse's space 8. In the presence of Ca2+, some laminins self.assemble into a polymer through the interaction of their three NH2 termini. When lung organotypic cultures are exposed to a proteolytic fragment of laminin-1 that blocks laminin polymerization. This fragment, referred as E4, comprises the outer globular region of laminin chain. Inhibition of laminin polymerization in lung organotypic cultures resulted in impaired basement membrane assembly and failure of epithelial cells to polarize.
Functions
Networks function, laminins bind to cell membranes through integrin receptors and other plasma membrane molecules, such as the dystroglycan glycoprotein complex and Lutheran blood group glycoprotein. These interactions contribute to cell attachment and differentiation, cell shape and movement, maintenance of tissue phenotype, and promotion of tissue survival
Pathology, dysfunctional structure of one particular laminin, laminin-211, is the cause of one form of congenital muscular dystrophy. Malfunctional laminin-521 in the kidney filter causes leakage of protein into the urine and nephrotic syndrome 9.
In cell structure, recent studies have demonstrated that laminins can be used to culture cells, such as pluripotent stem cells, that are difficult to culture on other substrates. Laminin-111 as well as a mixture of laminins 511 and 521 from human placenta have been used10.
In neural development, Laminin-111 is a major substrate along which nerve axons will grow, both in vivo and in vitro. The presence of laminin-1 can influence the growth cone. For example, growth cones are repelled by netrin when grown on laminin-111, but are attracted to netrin when grown on fibronectin.
References
1. Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR (1979). Laminin – a glycoprotein from basement membranes. J Biol Chem., 254(19):9933-9937.
2. Engel. J (1993). Structure and function of laminin. In Molecular and cellular aspects of basement membranes. Academic Press., 43:147-176.
3. Timpi, R. (1996). Macromolecular organization of basement membrane. Opin.Cell Bioi., 8:618-624.
4. Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E, Jones JC, Kleinman HK, Marinkovich MP, Martin GR, Mayer U, Meneguzzi G, Miner JH, Miyazaki K, Patarroyo M, Paulsson M, Quaranta V, Sanes JR, Sasaki T, Sekiguchi K, Sorokin LM, Talts JF, Tryggvason K, Uitto J, Virtanen I, von der Mark K, Wewer UM, Yamada Y, Yurchenco PD (2005). A simplified laminin nomenclature. Matrix Biol., 24 (5):326-332.
5. Haralson MA, John RH (1995). Extracellular matrix: a practical approach. Ithaca, N.Y: IRL Press.
6. Burgeson RE, Chiquet M, Deutzmann R, Ekblom P, Engel J, Kleinman H (1994). A new nomenclature for the laminins. Matrix Biol., 14:209-211.
7. Aumailley M, Smyth N (1998). The role of laminins in basement membrane function. J Anat., 193:1-21.
8. Schaffner F, Poper H (1963). Capillarization of hepatic sinusoids in man. Gastroenterology, 44:239-242.
9. Yurchenko P and Batton BL (2009). Developmental and pathogenic mechanisms of basement membrane assembly. Curr Pharm Des., 15(12):1277-1294.
10. Domogatskaya A, Rodin S, Boutaud A, Tryggvason K (2008). Laminin-511 but not -332, -111, or -411 enables mouse embryonic stem cell self-renewal in vitro. Stem Cells, 26(11):2800-2809.
Exendins and Fragments
Definition
The exendins are peptides that are found in the salivary secretions of the Gila monster and the Mexican Bearded Lizard, reptiles that are endogenous to Arizona and Northern Mexico. Exendin-3 is present in the salivary secretions of Heloderma horridum (Mexican Beaded Lizard), and exendin-4 is present in the salivary secretions of Heloderm suspectum (Gila monster)
Related Peptides
The GLP-1 structurally related peptides exendin-4 and exendin (9-39) amide were found to act, in rat liver and skeletal muscle, as agonist and antagonist, respectively, of the GLP-1 (7-36) amide effects on glucose metabolism 2.
Discovery
In 1982, it was observed that the crude venom of the Gila monster Heloderma suspectum was a potent pancreatic secretagogue. Purification and sequencing of the active factors mediating this effect led to the discovery of the peptides helodermin and exendin-4 3.
Structural Characteristics
The exendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to GLP-1[7-36] NH2 2. An amino acid sequencing assay for peptides containing an amino-terminal histidine residue (His1) was used to isolate a 39-amino acid peptide, exendin-4, from H. suspectum venom. Exendin-4 differs from exendin-3 by two amino acid substitutions, Gly2-Glu3 in place of Ser2-Asp3, but is otherwise identical. The structural differences make exendin-4 distinct from exendin-3 in its bioactivity 4.
Mode of Action
In normal rats, exendin-4, like GLP-1 and insulin, enhanced glucose uptake. This effect, which is mediated to a certain extent by some kinases (PI3K/ PKB, p70s6k and MAPKs), may be caused by the peptide acting, at least in part, through the muscle GLP-1 receptors. Exendin-9 also stimulated the same kinases, except for PKB, but failed to modify basal glucose uptake 5. Pharmacological studies have led to reports that exendin-4 can act at GLP-1 receptors in vitro on certain insulin-secreting cells, at dispersed acinar cells from guinea pig pancreas, and at parietal cells from stomach; the peptide is also reported to stimulate somatostatin release and inhibit gastrin release in isolated stomach.
Exendin-3 and exendin-4 were reportedly found to stimulate cAMP production in, and amylase release from, pancreatic acinar cells.1
Functions
Like GLP-1 (7-36) amide, exendin-4 increased glycogen synthase activity and glucose incorporation into glycogen in both tissues and also stimulated exogenous D -glucose utilization and oxidation in muscle. These effects of GLP-1(7-36) amide and exendin-4 were inhibited by exendin (9-39) amide 2. Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, and related products and methods are useful, for example, in the treatment of diabetes, including Type 1, Type 2, and gestational diabetes, in the treatment of disorders which would be benefited by agents which modulate plasma glucose levels or suppress glucagon secretion, and in the treatment of disorders which would be benefited by the administration of agents useful in modulating the rate of gastric emptying or food intake, including obesity, eating disorders, insulin-resistance syndrome, and triglyceride levels, and to treat subjects suffering from dyslipidemia. The methods are also useful for lowering plasma lipid levels, reducing cardiac risk, reducing appetite, and reducing the weight of subjects.1
References
1. Eng J, Andrews PC, Kleinman WA, Singh L, Raufman JP (1990). Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J Biol Chem., 265(33):20259-20262
2. Alcántara AI, Morales M, Delgado E, López-Delgado MI, Clemente F, Luque MA, Malaisse WJ, Valverde I, Villanueva-Peñacarrillo ML (1997). Exendin-4 Agonist and Exendin(9-39)amide Antagonist of the GLP-1(7-36)amide Effects in Liver and Muscle. Archives of Biochemistry and Biophysics., 341(1):1-7.
3. Pohl M, Wank SA (1998). Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J Biol Chem., 273(16):9778-9784.
4. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem., 267(11):7402-7405.
5. Sancho V, Trigo MV, González N, Valverde I, Malaisse WJ, Villanueva-Peñacarrillo ML (2005). Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol., 35(1):27-38.
The exendins are peptides that are found in the salivary secretions of the Gila monster and the Mexican Bearded Lizard, reptiles that are endogenous to Arizona and Northern Mexico. Exendin-3 is present in the salivary secretions of Heloderma horridum (Mexican Beaded Lizard), and exendin-4 is present in the salivary secretions of Heloderm suspectum (Gila monster)
Related Peptides
The GLP-1 structurally related peptides exendin-4 and exendin (9-39) amide were found to act, in rat liver and skeletal muscle, as agonist and antagonist, respectively, of the GLP-1 (7-36) amide effects on glucose metabolism 2.
Discovery
In 1982, it was observed that the crude venom of the Gila monster Heloderma suspectum was a potent pancreatic secretagogue. Purification and sequencing of the active factors mediating this effect led to the discovery of the peptides helodermin and exendin-4 3.
Structural Characteristics
The exendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to GLP-1[7-36] NH2 2. An amino acid sequencing assay for peptides containing an amino-terminal histidine residue (His1) was used to isolate a 39-amino acid peptide, exendin-4, from H. suspectum venom. Exendin-4 differs from exendin-3 by two amino acid substitutions, Gly2-Glu3 in place of Ser2-Asp3, but is otherwise identical. The structural differences make exendin-4 distinct from exendin-3 in its bioactivity 4.
Mode of Action
In normal rats, exendin-4, like GLP-1 and insulin, enhanced glucose uptake. This effect, which is mediated to a certain extent by some kinases (PI3K/ PKB, p70s6k and MAPKs), may be caused by the peptide acting, at least in part, through the muscle GLP-1 receptors. Exendin-9 also stimulated the same kinases, except for PKB, but failed to modify basal glucose uptake 5. Pharmacological studies have led to reports that exendin-4 can act at GLP-1 receptors in vitro on certain insulin-secreting cells, at dispersed acinar cells from guinea pig pancreas, and at parietal cells from stomach; the peptide is also reported to stimulate somatostatin release and inhibit gastrin release in isolated stomach.
Exendin-3 and exendin-4 were reportedly found to stimulate cAMP production in, and amylase release from, pancreatic acinar cells.1
Functions
Like GLP-1 (7-36) amide, exendin-4 increased glycogen synthase activity and glucose incorporation into glycogen in both tissues and also stimulated exogenous D -glucose utilization and oxidation in muscle. These effects of GLP-1(7-36) amide and exendin-4 were inhibited by exendin (9-39) amide 2. Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, and related products and methods are useful, for example, in the treatment of diabetes, including Type 1, Type 2, and gestational diabetes, in the treatment of disorders which would be benefited by agents which modulate plasma glucose levels or suppress glucagon secretion, and in the treatment of disorders which would be benefited by the administration of agents useful in modulating the rate of gastric emptying or food intake, including obesity, eating disorders, insulin-resistance syndrome, and triglyceride levels, and to treat subjects suffering from dyslipidemia. The methods are also useful for lowering plasma lipid levels, reducing cardiac risk, reducing appetite, and reducing the weight of subjects.1
References
1. Eng J, Andrews PC, Kleinman WA, Singh L, Raufman JP (1990). Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J Biol Chem., 265(33):20259-20262
2. Alcántara AI, Morales M, Delgado E, López-Delgado MI, Clemente F, Luque MA, Malaisse WJ, Valverde I, Villanueva-Peñacarrillo ML (1997). Exendin-4 Agonist and Exendin(9-39)amide Antagonist of the GLP-1(7-36)amide Effects in Liver and Muscle. Archives of Biochemistry and Biophysics., 341(1):1-7.
3. Pohl M, Wank SA (1998). Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J Biol Chem., 273(16):9778-9784.
4. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem., 267(11):7402-7405.
5. Sancho V, Trigo MV, González N, Valverde I, Malaisse WJ, Villanueva-Peñacarrillo ML (2005). Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol., 35(1):27-38.
Receptor Specific Enkephalins
Definition
The enkephalins are two pentapeptides with pharmacological properties similar to narcotic drugs. These peptides are widely distributed in the central nervous system (CNS). There are two fully processed peptides: Met-enkephalin (YGGFM) and Leu-enkephalin (YGGFL), with methionine and leucine as C-terminal amino acid. Other cleavage products such as YGGFMRF, YGGFMRGL and YGGFMRRV-amide (metorphamide) have been described. Met- and Leu-enkephalin have relative preference for the d-opioid receptor, while the C-terminally extended enkephalins have relatively high affinity for all opioid receptors 1.
Related Peptides
The endogenous opioid peptides all contain the enkephalin sequence Tyr-Gly-Gly-Phe-Met and Tyr-Gly-Gly-Phe-Leu at their amino terminus. Three distinct families of these peptides (endorphins, enkephalins and dynorphins) are present in different neuronal pathways within the CNS. Molecular genetics have shown that these three families of opioid peptides are derived from three distinct precursors. Pro-opiomelanocortin gives rise to the endorphins, as well as adrenocorticotropic hormone (ACTH) and the melanotropic hormones (MSH's). Met-enkephalin, Leu-enkephalin and the related heptapeptide Met-enkephalin-Arg6-Phe7 and octapeptide Met- enkephalin-Arg6-Gly7-Leu8 are derived from proenkephalin. The third family is derived from prodynorphin and includes dynorphin A, dynorphin B (also known as rimorphin) and alpha- and beta-neo-endorphin. The structure of the genes coding for these precursors are similar, suggesting the possibility of one common ancestral gene. The most common scheme for enzymatic maturation of precursors proposes the action of a trypsin-like endopeptidase followed by a carboxypeptidase B-like exopeptidase. Endo-oligopeptidase A, an enzyme, known to hydrolyze the Phe5-Ser6 bond of bradykinin and the Arg8-Arg9 bond of neurotensin, has also been shown to produce, by a single cleavage, Leu-enkephalin or Met-enkephalin from small enkephalin-containing peptides 1.
Discovery
In 1974 John Hughes and Hans Kosterlitz of Scotland discovered that enkephalins are produced in the brains of vertebrates, serving as a kind of opioid receptor and regulating pain pathways leading from peripheral nerves to the brain 2.
Structural characteristics
The mass spectrometric studies revealed that the natural enkephalin was a mixture of two pentapeptides, i. e. Met-enkephalin (H-Tyr-Gly-Gly-Phe-Met-OH) and Leu-enkephalin (H-Try-Gly-Gly-Phe-Leu-OH) in the ratio of 3 or 4 to 1 2. The structures of Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) have been determined from single crystal x-ray diffraction studies. The Met-enkephalin structure consists of dimers forming antiparallel-sheets extending in the monoclinic ac plane with 10.6 water molecules per dimer. The two molecules, related by pseudo two-fold axes, have similar backbone conformations and similar tyrosine and phenylalanine side-chain conformations. Leu-enkephalin crystallizes as a monohydrate that is isomorphous with the Met-enkephalin structure with respect to the ß-sheet but different with respect to the tyrosine and phenylalanine side-chain conformations and water content. The peptide chains in both structures are fully extended and more nearly planar than pleated. The detailed three-dimensional information on three different forms of Leu-enkephalin and one form of Met-enkephalin provide data on minimum energy conformations of these important peptides, which serve as models for the receptor-bound conformation3.
Mode of Action
Enkephalin regulates nociception through opioid receptor mediated signaling pathways. Short ProEnk peptides, such as Leu- and Met-enkephalin are selective for d-opioid receptors, but C-terminally extended peptides such as Met-Enk-Arg-Gly-Leu and Met-Enk-Arg-Phe have a high affinity to µ, d, ? receptors 4.
Receptor Specific Enkephalins:
1. (D-Ala2,D-Leu5)-Enkephalin / DADLE : H-Tyr-D-Ala-Gly-Phe-D-Leu-OH : DADLE has generally served as the putative, prototypical d-opioid receptor ligand. It is more potent and selective than Leu-enkephalin or Met-enkephalin in the MVD versus GPI bioassay systems and more potent and approximately as selective as Leu-enkephalin in binding assays. It shows roughly the same antinociceptive activity as ß-endorphin. [5-8]
2. (D-Ala2,N-Me-Phe4,methionin(O)-ol5)-Enkephalin / DAMME: H-Tyr-D-Ala-Gly-N-Me-Phe-methionin(O)-ol: DAMME shows only slight preference for µ-receptors over d-receptors and has no significant affinity for K-receptors. DAMME exerts a potent analgesic effect after systemic administration. It is one of the best-known analogs that has undergone fairly extensive clinical testing. [9-13]
3. (D-Ala2,N-Me-Phe4,glycinol5)-Enkephalin / DAMGO or DAGO: H-Tyr-D-Ala-Gly-N-Me-Phe-glycinol : µ-Receptor-specific enkephalin analog.[14, 15]
4. (D-Pen2,Pen5)-Enkephalin / DPLPE: H-Tyr-D-Pen-Gly-Phe-Pen-OH: This enkephalin analog exhibits an increase in d-receptor selectivity by an order of magnitude. [16]
5. (D-Ser2)-Leu-Enkephalin-Thr: H-Tyr-D-Ser-Gly-Phe-Leu-Thr-OH: This hexapeptide exhibits a very high specificity for the d-receptor. [17-18]
6. (D-Thr2)-Leu-Enkephalin-Thr: H-Tyr-D-Thr-Gly-Phe-Leu-Thr-OH and (D-Cys(tBu)2,Thr(tBu)6)-Leu-Enkephalin-Thr: H-Tyr-D-Cys(tBu)-Gly-Phe-Leu-Thr(tBu)-OH: Very potent d-receptor-specific enkephalin analogs. [19]
Functions
Enkephalins are opioid peptides that bridge the neuroendocrine and immune systems.
Enkephalins, pentapeptides containing the consensus Tyr-Gly-Gly-Phe-Xaa sequence, are the smallest of the molecules with pain killing or opiate activity. Enkephalins are found in the thalamus of the brain and in some parts of the spinal cord that transmit pain impulses. In the spinal cord, enkephalins inhibit painful sensations by reacting with specific receptor sites on the sensory nerve endings. Nerve endings of the central nervous system (CNS) and the adrenal medulla release these naturally occurring morphine-like substances. Enkephalins bind to opiate receptors and release controlled levels of pain.
Leu-enkephalin is an endogenous agonist for the receptors that are stimulated by opiate alkaloids. It has multiple effects on the CNS, including the neuroendocrine hypothalamus. Leu-enkephalin also controls gonadal function.[20]
Met-enkephalin is involved in phenomena associated with modulated pain perception, regulation of memory and emotional conditions, food and liquid consumption and regulation of immunological system. It also has an impact on the digestive system motility, gastric as well as in pancreatic secretion and metabolism of carbohydrates.[21, 22]
References
1. Rossier J. 1988. [Biosynthesis of opioid peptides]. Ann Endocrinol (Paris). 1988;49(4-5):371-3.
2. S.K. KULKARNI . 1977. Enkephalins : Possible Neurotransmitters? Ind.J. Pharmac. 9 (2) 125-129 (1977).
3. J. F. Griffin, D. A. Langs, G. D. Smith, T. L. Blundell, I. J. Tickle, and S. Bedarkar. 1986. The crystal structures of [Met5]enkephalin and a third form of [Leu5]enkephalin: Observations of a novel pleated 18-sheet (enkephalin conformation/opioid peptides/anti-parallel planar ß-sheet) Proc. Natl. Acad. Sci, Vol. 83, pp. 3272-3276, May 1986.
4. Mansour A, Hoversten MT, Taylor LP, Watson SJ, Akil H. 1995. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. 1995 Nov 27; 700(1-2):89-98.
5. Wei, E. T., Tseng, L. F., Loh, H. H., and Li, C. H .1977. Comparison of the behavioral effects of ß-endorphin and enkephalin analogs. Life Sci., 21: 321-328.
6. Pfeiffer A, Herz A.1982. Different type of opiate agonists inter- act distinguishability with mu, delta and kappa opiates binding sites. Life Sci 31:1355- 1358
7. A.H. Mulder, G. Wardeh, F. Hogenboom, A.L. Frankhuyzen. 1984. Kappa and delta opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release, Nature 308 (1984) 278– 280.
8. N.A.Sharif and J.Hughes, 1989. Discrete mapping of brain Mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. Peptides. 1989 May-Jun;10(3):499-522.
9. D.Roemer et al., 1977. A synthetic enkephalin analogue with prolonged parenteral and oral analgesic activity. Nature 268, 547 - 549 (11 August 1977)
10. W.A.Stubbs et al., 1978. Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet ii (1978), pp. 1225–1227.
11. von Graffenried B, del Pozo E, Roubicek J, Krebs E, Poldinger W, Burmeister P, Kerp L. 1978. Effects of the synthetic enkephalin analogue FK 33-824 in man. Nature. 1978 Apr 20; 272(5655):729–730.
12. B.Allolio et al., 1986. FK 33-824, a Met-Enkephalin Analog, Blocks Corticotropin-Releasing Hormone-Induced Adrenocorticotropin Secretion in Normal Subjects but not in Patients with Cushing’s Disease. J Clin Endocrinol Metab 1986 63: 1427-1431.
13. P.W.Schiller, 1991. Development of receptor-specific opioid peptide analogs. Prog. Med. Chem. 28 (1991), pp. 301–340.
14. Handa, B.K.; Lane, A.C.; Lord, J.A.H.; Morgan, B.A.; Ranee, M.J.; Smith, C.F.C. 1981. Analog of ß-LPH 61–64 possessing selective agonist activity of mu opiate receptors. Eur. J. Pharmacol. 70:531–540(1981).
15. J. Kowalski. 1998. Immunomodulatory action of class µ-, d- and ?-opioid receptor agonists in mice. Neuropeptides 32 (1998), pp. 301–306.
16. H I Mosberg, R Hurst, V J Hruby, K Gee, H I Yamamura, J J Galligan, and T F Burks. 1983. Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. PNAS October 1, 1983 vol. 80 no. 19 5871-5874.
17. Gacel G, Fournie-Zaluski MC, Roques BP (1980) D-tyr-ser-gly-phe-leu- thr, a highly preferential ligand for 6-opiate receptors. FEBS Letters. 118:245-247.
18. David M, Moisand C, Meunier JC, Morgat JL, Gacel G, Roques BP. 1982.[3H]Tyr-D-Ser-Gly-Phe-Leu-Thr: a specific probe for the delta-opiate receptor subtype in brain membranes. Eur J Pharmacol. 1982 Mar 12;78(3):385–387
19. Zajac JM, Gacel G, Petit F, Dodey P, Rossignol P, Roques BP. 1983. Deltakephalin, Tyr-D-Thr-Gly-Phe-Leu-Thr: a new highly potent and fully specific agonist for opiate delta-receptors. Biochem Biophys Res Commun. 1983 Mar 16;111(2):390–397.
20. Dudás, B. and I. Merchenthaler et al. 2003. Close Juxtapositions between LHRH Immunoreactive Neurons and Substance P Immunoreactive Axons in the Human Diencephalon .J. Clin. Endo.Met. 88, 1842 (2003).
21. Ning Zhang, Dave Hodge, Thomas J. Rogers, and Joost J. Oppenheim (2003); Ca2+-independent Protein Kinase Cs Mediate Heterologous Desensitization of Leukocyte Chemokine Receptors by Opioid Receptors. J. Biol. Chem., Vol. 278, Issue 15, 12729-12736, April 11, 2003.
22. Owczarek D, Garlicka M, Pierzchala-Koziec K, Skulina D, Szulewski P. 2003. Met-enkephalin plasma concentration and content in liver tissue in patients with primary biliary cirrhosis. Przegl Lek 2003; 60: 461-466.
The enkephalins are two pentapeptides with pharmacological properties similar to narcotic drugs. These peptides are widely distributed in the central nervous system (CNS). There are two fully processed peptides: Met-enkephalin (YGGFM) and Leu-enkephalin (YGGFL), with methionine and leucine as C-terminal amino acid. Other cleavage products such as YGGFMRF, YGGFMRGL and YGGFMRRV-amide (metorphamide) have been described. Met- and Leu-enkephalin have relative preference for the d-opioid receptor, while the C-terminally extended enkephalins have relatively high affinity for all opioid receptors 1.
Related Peptides
The endogenous opioid peptides all contain the enkephalin sequence Tyr-Gly-Gly-Phe-Met and Tyr-Gly-Gly-Phe-Leu at their amino terminus. Three distinct families of these peptides (endorphins, enkephalins and dynorphins) are present in different neuronal pathways within the CNS. Molecular genetics have shown that these three families of opioid peptides are derived from three distinct precursors. Pro-opiomelanocortin gives rise to the endorphins, as well as adrenocorticotropic hormone (ACTH) and the melanotropic hormones (MSH's). Met-enkephalin, Leu-enkephalin and the related heptapeptide Met-enkephalin-Arg6-Phe7 and octapeptide Met- enkephalin-Arg6-Gly7-Leu8 are derived from proenkephalin. The third family is derived from prodynorphin and includes dynorphin A, dynorphin B (also known as rimorphin) and alpha- and beta-neo-endorphin. The structure of the genes coding for these precursors are similar, suggesting the possibility of one common ancestral gene. The most common scheme for enzymatic maturation of precursors proposes the action of a trypsin-like endopeptidase followed by a carboxypeptidase B-like exopeptidase. Endo-oligopeptidase A, an enzyme, known to hydrolyze the Phe5-Ser6 bond of bradykinin and the Arg8-Arg9 bond of neurotensin, has also been shown to produce, by a single cleavage, Leu-enkephalin or Met-enkephalin from small enkephalin-containing peptides 1.
Discovery
In 1974 John Hughes and Hans Kosterlitz of Scotland discovered that enkephalins are produced in the brains of vertebrates, serving as a kind of opioid receptor and regulating pain pathways leading from peripheral nerves to the brain 2.
Structural characteristics
The mass spectrometric studies revealed that the natural enkephalin was a mixture of two pentapeptides, i. e. Met-enkephalin (H-Tyr-Gly-Gly-Phe-Met-OH) and Leu-enkephalin (H-Try-Gly-Gly-Phe-Leu-OH) in the ratio of 3 or 4 to 1 2. The structures of Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and Leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) have been determined from single crystal x-ray diffraction studies. The Met-enkephalin structure consists of dimers forming antiparallel-sheets extending in the monoclinic ac plane with 10.6 water molecules per dimer. The two molecules, related by pseudo two-fold axes, have similar backbone conformations and similar tyrosine and phenylalanine side-chain conformations. Leu-enkephalin crystallizes as a monohydrate that is isomorphous with the Met-enkephalin structure with respect to the ß-sheet but different with respect to the tyrosine and phenylalanine side-chain conformations and water content. The peptide chains in both structures are fully extended and more nearly planar than pleated. The detailed three-dimensional information on three different forms of Leu-enkephalin and one form of Met-enkephalin provide data on minimum energy conformations of these important peptides, which serve as models for the receptor-bound conformation3.
Mode of Action
Enkephalin regulates nociception through opioid receptor mediated signaling pathways. Short ProEnk peptides, such as Leu- and Met-enkephalin are selective for d-opioid receptors, but C-terminally extended peptides such as Met-Enk-Arg-Gly-Leu and Met-Enk-Arg-Phe have a high affinity to µ, d, ? receptors 4.
Receptor Specific Enkephalins:
1. (D-Ala2,D-Leu5)-Enkephalin / DADLE : H-Tyr-D-Ala-Gly-Phe-D-Leu-OH : DADLE has generally served as the putative, prototypical d-opioid receptor ligand. It is more potent and selective than Leu-enkephalin or Met-enkephalin in the MVD versus GPI bioassay systems and more potent and approximately as selective as Leu-enkephalin in binding assays. It shows roughly the same antinociceptive activity as ß-endorphin. [5-8]
2. (D-Ala2,N-Me-Phe4,methionin(O)-ol5)-Enkephalin / DAMME: H-Tyr-D-Ala-Gly-N-Me-Phe-methionin(O)-ol: DAMME shows only slight preference for µ-receptors over d-receptors and has no significant affinity for K-receptors. DAMME exerts a potent analgesic effect after systemic administration. It is one of the best-known analogs that has undergone fairly extensive clinical testing. [9-13]
3. (D-Ala2,N-Me-Phe4,glycinol5)-Enkephalin / DAMGO or DAGO: H-Tyr-D-Ala-Gly-N-Me-Phe-glycinol : µ-Receptor-specific enkephalin analog.[14, 15]
4. (D-Pen2,Pen5)-Enkephalin / DPLPE: H-Tyr-D-Pen-Gly-Phe-Pen-OH: This enkephalin analog exhibits an increase in d-receptor selectivity by an order of magnitude. [16]
5. (D-Ser2)-Leu-Enkephalin-Thr: H-Tyr-D-Ser-Gly-Phe-Leu-Thr-OH: This hexapeptide exhibits a very high specificity for the d-receptor. [17-18]
6. (D-Thr2)-Leu-Enkephalin-Thr: H-Tyr-D-Thr-Gly-Phe-Leu-Thr-OH and (D-Cys(tBu)2,Thr(tBu)6)-Leu-Enkephalin-Thr: H-Tyr-D-Cys(tBu)-Gly-Phe-Leu-Thr(tBu)-OH: Very potent d-receptor-specific enkephalin analogs. [19]
Functions
Enkephalins are opioid peptides that bridge the neuroendocrine and immune systems.
Enkephalins, pentapeptides containing the consensus Tyr-Gly-Gly-Phe-Xaa sequence, are the smallest of the molecules with pain killing or opiate activity. Enkephalins are found in the thalamus of the brain and in some parts of the spinal cord that transmit pain impulses. In the spinal cord, enkephalins inhibit painful sensations by reacting with specific receptor sites on the sensory nerve endings. Nerve endings of the central nervous system (CNS) and the adrenal medulla release these naturally occurring morphine-like substances. Enkephalins bind to opiate receptors and release controlled levels of pain.
Leu-enkephalin is an endogenous agonist for the receptors that are stimulated by opiate alkaloids. It has multiple effects on the CNS, including the neuroendocrine hypothalamus. Leu-enkephalin also controls gonadal function.[20]
Met-enkephalin is involved in phenomena associated with modulated pain perception, regulation of memory and emotional conditions, food and liquid consumption and regulation of immunological system. It also has an impact on the digestive system motility, gastric as well as in pancreatic secretion and metabolism of carbohydrates.[21, 22]
References
1. Rossier J. 1988. [Biosynthesis of opioid peptides]. Ann Endocrinol (Paris). 1988;49(4-5):371-3.
2. S.K. KULKARNI . 1977. Enkephalins : Possible Neurotransmitters? Ind.J. Pharmac. 9 (2) 125-129 (1977).
3. J. F. Griffin, D. A. Langs, G. D. Smith, T. L. Blundell, I. J. Tickle, and S. Bedarkar. 1986. The crystal structures of [Met5]enkephalin and a third form of [Leu5]enkephalin: Observations of a novel pleated 18-sheet (enkephalin conformation/opioid peptides/anti-parallel planar ß-sheet) Proc. Natl. Acad. Sci, Vol. 83, pp. 3272-3276, May 1986.
4. Mansour A, Hoversten MT, Taylor LP, Watson SJ, Akil H. 1995. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. 1995 Nov 27; 700(1-2):89-98.
5. Wei, E. T., Tseng, L. F., Loh, H. H., and Li, C. H .1977. Comparison of the behavioral effects of ß-endorphin and enkephalin analogs. Life Sci., 21: 321-328.
6. Pfeiffer A, Herz A.1982. Different type of opiate agonists inter- act distinguishability with mu, delta and kappa opiates binding sites. Life Sci 31:1355- 1358
7. A.H. Mulder, G. Wardeh, F. Hogenboom, A.L. Frankhuyzen. 1984. Kappa and delta opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release, Nature 308 (1984) 278– 280.
8. N.A.Sharif and J.Hughes, 1989. Discrete mapping of brain Mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. Peptides. 1989 May-Jun;10(3):499-522.
9. D.Roemer et al., 1977. A synthetic enkephalin analogue with prolonged parenteral and oral analgesic activity. Nature 268, 547 - 549 (11 August 1977)
10. W.A.Stubbs et al., 1978. Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet ii (1978), pp. 1225–1227.
11. von Graffenried B, del Pozo E, Roubicek J, Krebs E, Poldinger W, Burmeister P, Kerp L. 1978. Effects of the synthetic enkephalin analogue FK 33-824 in man. Nature. 1978 Apr 20; 272(5655):729–730.
12. B.Allolio et al., 1986. FK 33-824, a Met-Enkephalin Analog, Blocks Corticotropin-Releasing Hormone-Induced Adrenocorticotropin Secretion in Normal Subjects but not in Patients with Cushing’s Disease. J Clin Endocrinol Metab 1986 63: 1427-1431.
13. P.W.Schiller, 1991. Development of receptor-specific opioid peptide analogs. Prog. Med. Chem. 28 (1991), pp. 301–340.
14. Handa, B.K.; Lane, A.C.; Lord, J.A.H.; Morgan, B.A.; Ranee, M.J.; Smith, C.F.C. 1981. Analog of ß-LPH 61–64 possessing selective agonist activity of mu opiate receptors. Eur. J. Pharmacol. 70:531–540(1981).
15. J. Kowalski. 1998. Immunomodulatory action of class µ-, d- and ?-opioid receptor agonists in mice. Neuropeptides 32 (1998), pp. 301–306.
16. H I Mosberg, R Hurst, V J Hruby, K Gee, H I Yamamura, J J Galligan, and T F Burks. 1983. Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. PNAS October 1, 1983 vol. 80 no. 19 5871-5874.
17. Gacel G, Fournie-Zaluski MC, Roques BP (1980) D-tyr-ser-gly-phe-leu- thr, a highly preferential ligand for 6-opiate receptors. FEBS Letters. 118:245-247.
18. David M, Moisand C, Meunier JC, Morgat JL, Gacel G, Roques BP. 1982.[3H]Tyr-D-Ser-Gly-Phe-Leu-Thr: a specific probe for the delta-opiate receptor subtype in brain membranes. Eur J Pharmacol. 1982 Mar 12;78(3):385–387
19. Zajac JM, Gacel G, Petit F, Dodey P, Rossignol P, Roques BP. 1983. Deltakephalin, Tyr-D-Thr-Gly-Phe-Leu-Thr: a new highly potent and fully specific agonist for opiate delta-receptors. Biochem Biophys Res Commun. 1983 Mar 16;111(2):390–397.
20. Dudás, B. and I. Merchenthaler et al. 2003. Close Juxtapositions between LHRH Immunoreactive Neurons and Substance P Immunoreactive Axons in the Human Diencephalon .J. Clin. Endo.Met. 88, 1842 (2003).
21. Ning Zhang, Dave Hodge, Thomas J. Rogers, and Joost J. Oppenheim (2003); Ca2+-independent Protein Kinase Cs Mediate Heterologous Desensitization of Leukocyte Chemokine Receptors by Opioid Receptors. J. Biol. Chem., Vol. 278, Issue 15, 12729-12736, April 11, 2003.
22. Owczarek D, Garlicka M, Pierzchala-Koziec K, Skulina D, Szulewski P. 2003. Met-enkephalin plasma concentration and content in liver tissue in patients with primary biliary cirrhosis. Przegl Lek 2003; 60: 461-466.
Protein Tyrosine Phosphatase 1B
Definition
Protein Tyrosine Phosphatase 1B (PTP-1B) is a non-receptor PTP. PTP-1B is a member of the protein tyrosine phosphatase family of enzymes.
Discovery
PTP-1B is a widely expressed non-receptor PTP that was originally identified by Fischer and his collaborators from human placenta 1 and determined the amino acid sequence of the major soluble and particulate PTPase, PTP-1B.
Structural Characteristics
PTP-1B possesses a catalytic domain characterized by the 11-amino acid sequence motif, (I/V)HCXAGXXR(S/T)G. This motif contains cysteine (Cys215) and arginine (Arg221) residues critical for the catalytic activity of the enzyme 2. The cDNA sequences for human 3 and rat 4 PTP-1B predict a protein of 50 kDa with 435 and 432 amino acids, respectively. The conserved phosphatase domain of PTP-1B is contained within the domain spanning residues 30 to 278. The COOH-terminal noncatalytic extension of the protein serves a regulatory function. The COOH-terminal 35 residues target the enzyme to the cytoplasmic face of the endoplasmic reticulum 5, whereas the preceding 122 residues are predominantly hydrophilic and contain sites for serine phosphorylation. Recently, the crystal structure of the 321-residue (37-kDa) form of human PTP-1B has been determined, revealing the structural features that provide the protein with its specific enzymatic capacity for phosphotyrosine 6.
Mode of Action
PTP-1B interacts with insulin receptor and negatively regulates insulin signalling by an N-terminal binding7 and it also negatively regulates integrin signalling through a proline-rich region present in the C-terminus 8. A study indicate that PTP1B mutants that are defective in Src homology 3 domain binding fully retain the ability to inhibit insulin signalling, whereas mutants defective in insulin-receptor binding fully retain the ability to inhibit integrin signalling. In contrast, both the C-terminal proline-rich region and the tandem tyrosine residues present in the N-terminal region are required for the activation of Src family kinases. These data show that PTP1B can independently regulate insulin and integrin signals, and that Src might represent a convergence point for regulating signal transduction by this phosphatase 9.
Functions
Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the PTP-1B gene:
Disruption of the mouse homolog of the gene encoding PTP-1B yielded healthy mice that, in the fed state, had blood glucose concentrations that were slightly lower and concentrations of circulating insulin that were one-half those of their PTP-1B+/+ littermates. The enhanced insulin sensitivity of the PTP-1B-/- mice was also evident in glucose and insulin tolerance tests. The PTP-1B-/- mice showed increased phosphorylation of the insulin receptor in liver and muscle tissue after insulin injection in comparison to PTP-1B+/+ mice. On a high-fat diet, the PTP-1B-/- and PTP-1B+/- mice were resistant to weight gain and remained insulin sensitive, whereas the PTP-1B+/+ mice rapidly gained weight and became insulin resistant. These results demonstrate that PTP-1B has a major role in modulating both insulin sensitivity and fuel metabolism, thereby establishing it as a potential therapeutic target in the treatment of type 2 diabetes and obesity 10.
PTP-1B Complexes with the Insulin Receptor in Vivo and Is Tyrosine-phosphorylated in the Presence of Insulin: In response to insulin, PTP-1B dephosphorylates 95- and 160-180-kDa tyrosine phosphorylated (PY) proteins. Anti-PTPase 1B antibodies coprecipitated a 95-kDa PY protein from insulin-stimulated cells, subsequently identified as the IR ß-subunit. Similarly, anti-IR antibodies coprecipitated the 50-kDa PY- PTP-1B protein from insulin-treated cells. To identify PTP-1B tyrosine (Tyr) residues that are phosphorylated in response to insulin, three candidate sites (Tyr66, Tyr152, and Tyr153) were replaced with phenylalanine. Replacing Tyr66 or Tyr152 and Tyr153 significantly reduced insulin-stimulated PTP-1B phosphotyrosine content, as well as its association with the IR. These results suggest that PTP-1B complexes with the autophosphorylated insulin receptor in intact cells, either directly or within a complex involving additional proteins 11. The interaction requires multiple tyrosine phosphorylation sites within both the receptor and PTP-1B.
References
1. Tonks NK, Diltz CD, Fischer EH (1988). Purification of the major protein-tyrosine-phosphatases of human placenta. J. Biol. Chem., 263:6722-6730.
2. Guan KL, Dixon JE (1991). Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate. J. Biol. Chem., 266:17026-17030.
3. Chernoff J, Schievella AR, Jost CA, Erickson RL, and Neel BG (1990). Cloning of a cDNA for a major human protein-tyrosine-phosphatase. PNAS, 87:2735-2739.
4. Guan KL, Haun RS, Watson SJ, Geahlen RL, and Dixon JE (1991). Cloning and expression of a protein-tyrosine-phosphatase. PNAS, 87:1501-1505.
5. Frangioni JV, Beahm PH, Shifrin V, Jost CA, Neel BG (1992). The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell, 68:545-560
6. Barford D, Flint AJ, Tonks NK. (1994). Crystal structure of human protein tyrosine phosphatase 1. Science, 263:1397-1404.
7. Dadke S, Kusari J, Chernoff J (2000). Down-regulation of insulin signaling by protein-tyrosine phosphatase 1B is mediated by an N-terminal binding region. J. Biol. Chem., 275(31):23642–23647.
8. Liu F, Hill DE, Chernoff J (1996). Direct binding of the proline-rich region of protein tyrosine phosphatase 1B to the Src homology 3 domain of p130(Cas). J. Biol. Chem. 271(49):31290–31295.
9. Dadke S, Chernoff J (2002). Interaction of protein tyrosine phosphatase (PTP) 1B with its substrates is influenced by two distinct binding domains. Biochem. J., 364: 377–383.
10. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, Kennedy BP (1999). Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine Phosphatase-1B Gene . Science 283(5407):1544-1548.
11. Bandyopadhyay D, Kusari A, Kenner KA, Liu F, Chernoff J, Gustafson TA, Kusari J (1997). Protein-Tyrosine Phosphatase 1B Complexes with the Insulin Receptor in Vivo and Is Tyrosine-phosphorylated in the Presence of Insulin. J. Biol. Chem., 272(3):1639-1645.
Protein Tyrosine Phosphatase 1B (PTP-1B) is a non-receptor PTP. PTP-1B is a member of the protein tyrosine phosphatase family of enzymes.
Discovery
PTP-1B is a widely expressed non-receptor PTP that was originally identified by Fischer and his collaborators from human placenta 1 and determined the amino acid sequence of the major soluble and particulate PTPase, PTP-1B.
Structural Characteristics
PTP-1B possesses a catalytic domain characterized by the 11-amino acid sequence motif, (I/V)HCXAGXXR(S/T)G. This motif contains cysteine (Cys215) and arginine (Arg221) residues critical for the catalytic activity of the enzyme 2. The cDNA sequences for human 3 and rat 4 PTP-1B predict a protein of 50 kDa with 435 and 432 amino acids, respectively. The conserved phosphatase domain of PTP-1B is contained within the domain spanning residues 30 to 278. The COOH-terminal noncatalytic extension of the protein serves a regulatory function. The COOH-terminal 35 residues target the enzyme to the cytoplasmic face of the endoplasmic reticulum 5, whereas the preceding 122 residues are predominantly hydrophilic and contain sites for serine phosphorylation. Recently, the crystal structure of the 321-residue (37-kDa) form of human PTP-1B has been determined, revealing the structural features that provide the protein with its specific enzymatic capacity for phosphotyrosine 6.
Mode of Action
PTP-1B interacts with insulin receptor and negatively regulates insulin signalling by an N-terminal binding7 and it also negatively regulates integrin signalling through a proline-rich region present in the C-terminus 8. A study indicate that PTP1B mutants that are defective in Src homology 3 domain binding fully retain the ability to inhibit insulin signalling, whereas mutants defective in insulin-receptor binding fully retain the ability to inhibit integrin signalling. In contrast, both the C-terminal proline-rich region and the tandem tyrosine residues present in the N-terminal region are required for the activation of Src family kinases. These data show that PTP1B can independently regulate insulin and integrin signals, and that Src might represent a convergence point for regulating signal transduction by this phosphatase 9.
Functions
Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the PTP-1B gene:
Disruption of the mouse homolog of the gene encoding PTP-1B yielded healthy mice that, in the fed state, had blood glucose concentrations that were slightly lower and concentrations of circulating insulin that were one-half those of their PTP-1B+/+ littermates. The enhanced insulin sensitivity of the PTP-1B-/- mice was also evident in glucose and insulin tolerance tests. The PTP-1B-/- mice showed increased phosphorylation of the insulin receptor in liver and muscle tissue after insulin injection in comparison to PTP-1B+/+ mice. On a high-fat diet, the PTP-1B-/- and PTP-1B+/- mice were resistant to weight gain and remained insulin sensitive, whereas the PTP-1B+/+ mice rapidly gained weight and became insulin resistant. These results demonstrate that PTP-1B has a major role in modulating both insulin sensitivity and fuel metabolism, thereby establishing it as a potential therapeutic target in the treatment of type 2 diabetes and obesity 10.
PTP-1B Complexes with the Insulin Receptor in Vivo and Is Tyrosine-phosphorylated in the Presence of Insulin: In response to insulin, PTP-1B dephosphorylates 95- and 160-180-kDa tyrosine phosphorylated (PY) proteins. Anti-PTPase 1B antibodies coprecipitated a 95-kDa PY protein from insulin-stimulated cells, subsequently identified as the IR ß-subunit. Similarly, anti-IR antibodies coprecipitated the 50-kDa PY- PTP-1B protein from insulin-treated cells. To identify PTP-1B tyrosine (Tyr) residues that are phosphorylated in response to insulin, three candidate sites (Tyr66, Tyr152, and Tyr153) were replaced with phenylalanine. Replacing Tyr66 or Tyr152 and Tyr153 significantly reduced insulin-stimulated PTP-1B phosphotyrosine content, as well as its association with the IR. These results suggest that PTP-1B complexes with the autophosphorylated insulin receptor in intact cells, either directly or within a complex involving additional proteins 11. The interaction requires multiple tyrosine phosphorylation sites within both the receptor and PTP-1B.
References
1. Tonks NK, Diltz CD, Fischer EH (1988). Purification of the major protein-tyrosine-phosphatases of human placenta. J. Biol. Chem., 263:6722-6730.
2. Guan KL, Dixon JE (1991). Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate. J. Biol. Chem., 266:17026-17030.
3. Chernoff J, Schievella AR, Jost CA, Erickson RL, and Neel BG (1990). Cloning of a cDNA for a major human protein-tyrosine-phosphatase. PNAS, 87:2735-2739.
4. Guan KL, Haun RS, Watson SJ, Geahlen RL, and Dixon JE (1991). Cloning and expression of a protein-tyrosine-phosphatase. PNAS, 87:1501-1505.
5. Frangioni JV, Beahm PH, Shifrin V, Jost CA, Neel BG (1992). The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell, 68:545-560
6. Barford D, Flint AJ, Tonks NK. (1994). Crystal structure of human protein tyrosine phosphatase 1. Science, 263:1397-1404.
7. Dadke S, Kusari J, Chernoff J (2000). Down-regulation of insulin signaling by protein-tyrosine phosphatase 1B is mediated by an N-terminal binding region. J. Biol. Chem., 275(31):23642–23647.
8. Liu F, Hill DE, Chernoff J (1996). Direct binding of the proline-rich region of protein tyrosine phosphatase 1B to the Src homology 3 domain of p130(Cas). J. Biol. Chem. 271(49):31290–31295.
9. Dadke S, Chernoff J (2002). Interaction of protein tyrosine phosphatase (PTP) 1B with its substrates is influenced by two distinct binding domains. Biochem. J., 364: 377–383.
10. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, Kennedy BP (1999). Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine Phosphatase-1B Gene . Science 283(5407):1544-1548.
11. Bandyopadhyay D, Kusari A, Kenner KA, Liu F, Chernoff J, Gustafson TA, Kusari J (1997). Protein-Tyrosine Phosphatase 1B Complexes with the Insulin Receptor in Vivo and Is Tyrosine-phosphorylated in the Presence of Insulin. J. Biol. Chem., 272(3):1639-1645.
Protein Tyrosine Phosphatase
Definition
Protein tyrosine phosphatases (PTPases) are the enzymes responsible for the selective dephosphorylation of tyrosine residues.
Discovery
Soon after the discovery of protein tyrosine kinases (PTKs), the presence of PTPases was deduced from experiments using cell lines transformed with temperature-sensitive v-src mutants. At the permissive temperature (36 ºC) the virus-transformed cells rapidly incorporated phosphate into tyrosine residues of proteins. However, when the temperature was raised to (41 ºC ) where the temperature-sensitive v-src kinase was inactive, the level of cellular tyrosine phosphates declined very rapidly to the basal level, presumably due to the activities of cellular PTPases 1. This important observation was followed by numerous attempts to identify and characterize PTPases 2.
Classification
The human genome encodes approximately 100 phosphatases that belong to the protein tyrosine phosphatase (PTP) superfamily, whose substrates range from proteins to phosphoinositides and mRNAs. The hallmark for this superfamily is the active site sequence C(X)5R, also known as the PTP signature motif. The PTPs are key regulatory components in signal transduction pathways and the importance of PTPs in the control of cellular signaling is well established. Based on structure and substrate specificity, the PTP super-family is divided into four distinct subfamilies: 1). pTyr specific PTPs, 2). Dual specificity phosphatases, 3). Cdc25 phosphatases, and 4). LMW PTPs. The PTPs have similar core structures made of a central parallel beta-sheet with flanking alpha-helices containing a beta-loop-alpha loop that encompasses the PTP signature motif
Structural Characteristics
The PTP family of enzymes dephosphorylates target signaling proteins and are involved in the diverse regulation of numerous cell functions. PTPs comprise a large gene-family with the minimal catalytic motif CX5R, where C is the cysteine nucleophile that attacks the phosphate group, R is the arginine residue that binds phosphate and stabilizes the transition state, and X represents any amino acid. A large subgroup of the PTPs are capable of efficient hydrolysis of both phosphotyrosine and phosphothreonine/serine residues and are often referred to as dual-specificity PTPs. Members of the PTP family can be soluble or membrane-associated proteins, as in the receptor-like PTPs. The common feature of these phosphatases appears to be the basic catalytic mechanism involving the formation of a phospho-cysteinyl enzyme intermediate, using the conserved cysteine, arginine, and general acid/base aspartate residue. The catalytic domain of PTPs consists of an a/ß fold composed of a highly twisted core of ß-strands flanked by a-helices. Domains outside of the catalytic fold serve as regulatory and/or targeting modules 4, 5.
Mode of Action
PTKs and their associated signaling pathways are crucial for the regulation of numerous cell functions including growth, mitogenesis, motility, cell-cell interactions, metabolism, gene transcription, and the immune response. Since tyrosine phosphorylation is reversible and dynamic in vivo, the phosphorylation states of proteins are governed by the opposing actions of PTKs and PTPs. In this light, both PTKs and PTPs play equally important roles in signal transduction in eukaryotic cells, and comprehension of mechanisms behind the reversible pTyr-dependent modulation of protein function and cell physiology must necessarily encompass the characterization of PTPs as well as PTKs 4.
Functions
Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants: Zinc ions have an insulin-like (insulinomimetic) effect. A particularly sensitive target of zinc ions is protein tyrosine phosphatase 1B (PTP 1B), a key regulator of the phosphorylation state of the insulin receptor. Tyrosine phosphatases seem to be regulated jointly by insulin-induced redox (hydrogen peroxide) signaling, which results in their oxidative inactivation, and by their zinc inhibition after oxidative zinc release from other proteins. In diabetes, the significant oxidative stress and associated changes in zinc metabolism modify the cell’s response and sensitivity to insulin. Zinc deficiency activates stress pathways and may result in a loss of tyrosine phosphatase control, thereby causing insulin resistance 6.
Protein tyrosine phosphatases and the immune response: Reversible tyrosine phosphorylation of proteins is a key regulatory mechanism for numerous important aspects of eukaryotic physiology and is catalyzed by kinases and phosphatases. Together, cells of the immune system express at least half of the 107 PTP genes in the human genome, most of which encode multidomain proteins that contain protein- and phospholipid-interaction domains. Recent evidence show, that even subtle alteration in PTPs can cause immune dysfunction and human disease 7.
References
1. Friis RR, Jockusch BM, Boschek CB, Ziemiecki A, Rübsamen H, Bauer H (1979). Transformation-defective, temperature sensitive mutants of Rous sarcoma virus have a reversibly defective src-gene product. Cold. Spring. Harbor. Symp Quant. Biol., 44:1007-1012.
2. Saito H, Streuli M (1991). Molecular Characterization of Protein Tyrosine. Cell Growth & Differentiation, 2:59-65.
3. Wang WQ, Sun JP, Zhang ZY (2003). An overview of the protein tyrosine phosphatase superfamily. Curr Top Med Chem., 3(7):739-748.
4. Burke TR Jr, Zhang ZY (1998). Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers, 47(3):225-241.
5. Zhang ZY (1998). Protein-tyrosine phosphatases: biological function, structural characteristics, and mechanism of catalysis. Crit. Rev. Biochem. Mol. Biol., 33(1):1-52.
6. Haase H, Maret W (2005). Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants. BioMetals, 18:333–338.
7. Mustelin T, Vang T, Bottini N (2005). Protein tyrosine phosphatases and the immune response. Nat. Rev. Immunol., 5(1):43-57.
Protein tyrosine phosphatases (PTPases) are the enzymes responsible for the selective dephosphorylation of tyrosine residues.
Discovery
Soon after the discovery of protein tyrosine kinases (PTKs), the presence of PTPases was deduced from experiments using cell lines transformed with temperature-sensitive v-src mutants. At the permissive temperature (36 ºC) the virus-transformed cells rapidly incorporated phosphate into tyrosine residues of proteins. However, when the temperature was raised to (41 ºC ) where the temperature-sensitive v-src kinase was inactive, the level of cellular tyrosine phosphates declined very rapidly to the basal level, presumably due to the activities of cellular PTPases 1. This important observation was followed by numerous attempts to identify and characterize PTPases 2.
Classification
The human genome encodes approximately 100 phosphatases that belong to the protein tyrosine phosphatase (PTP) superfamily, whose substrates range from proteins to phosphoinositides and mRNAs. The hallmark for this superfamily is the active site sequence C(X)5R, also known as the PTP signature motif. The PTPs are key regulatory components in signal transduction pathways and the importance of PTPs in the control of cellular signaling is well established. Based on structure and substrate specificity, the PTP super-family is divided into four distinct subfamilies: 1). pTyr specific PTPs, 2). Dual specificity phosphatases, 3). Cdc25 phosphatases, and 4). LMW PTPs. The PTPs have similar core structures made of a central parallel beta-sheet with flanking alpha-helices containing a beta-loop-alpha loop that encompasses the PTP signature motif
Structural Characteristics
The PTP family of enzymes dephosphorylates target signaling proteins and are involved in the diverse regulation of numerous cell functions. PTPs comprise a large gene-family with the minimal catalytic motif CX5R, where C is the cysteine nucleophile that attacks the phosphate group, R is the arginine residue that binds phosphate and stabilizes the transition state, and X represents any amino acid. A large subgroup of the PTPs are capable of efficient hydrolysis of both phosphotyrosine and phosphothreonine/serine residues and are often referred to as dual-specificity PTPs. Members of the PTP family can be soluble or membrane-associated proteins, as in the receptor-like PTPs. The common feature of these phosphatases appears to be the basic catalytic mechanism involving the formation of a phospho-cysteinyl enzyme intermediate, using the conserved cysteine, arginine, and general acid/base aspartate residue. The catalytic domain of PTPs consists of an a/ß fold composed of a highly twisted core of ß-strands flanked by a-helices. Domains outside of the catalytic fold serve as regulatory and/or targeting modules 4, 5.
Mode of Action
PTKs and their associated signaling pathways are crucial for the regulation of numerous cell functions including growth, mitogenesis, motility, cell-cell interactions, metabolism, gene transcription, and the immune response. Since tyrosine phosphorylation is reversible and dynamic in vivo, the phosphorylation states of proteins are governed by the opposing actions of PTKs and PTPs. In this light, both PTKs and PTPs play equally important roles in signal transduction in eukaryotic cells, and comprehension of mechanisms behind the reversible pTyr-dependent modulation of protein function and cell physiology must necessarily encompass the characterization of PTPs as well as PTKs 4.
Functions
Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants: Zinc ions have an insulin-like (insulinomimetic) effect. A particularly sensitive target of zinc ions is protein tyrosine phosphatase 1B (PTP 1B), a key regulator of the phosphorylation state of the insulin receptor. Tyrosine phosphatases seem to be regulated jointly by insulin-induced redox (hydrogen peroxide) signaling, which results in their oxidative inactivation, and by their zinc inhibition after oxidative zinc release from other proteins. In diabetes, the significant oxidative stress and associated changes in zinc metabolism modify the cell’s response and sensitivity to insulin. Zinc deficiency activates stress pathways and may result in a loss of tyrosine phosphatase control, thereby causing insulin resistance 6.
Protein tyrosine phosphatases and the immune response: Reversible tyrosine phosphorylation of proteins is a key regulatory mechanism for numerous important aspects of eukaryotic physiology and is catalyzed by kinases and phosphatases. Together, cells of the immune system express at least half of the 107 PTP genes in the human genome, most of which encode multidomain proteins that contain protein- and phospholipid-interaction domains. Recent evidence show, that even subtle alteration in PTPs can cause immune dysfunction and human disease 7.
References
1. Friis RR, Jockusch BM, Boschek CB, Ziemiecki A, Rübsamen H, Bauer H (1979). Transformation-defective, temperature sensitive mutants of Rous sarcoma virus have a reversibly defective src-gene product. Cold. Spring. Harbor. Symp Quant. Biol., 44:1007-1012.
2. Saito H, Streuli M (1991). Molecular Characterization of Protein Tyrosine. Cell Growth & Differentiation, 2:59-65.
3. Wang WQ, Sun JP, Zhang ZY (2003). An overview of the protein tyrosine phosphatase superfamily. Curr Top Med Chem., 3(7):739-748.
4. Burke TR Jr, Zhang ZY (1998). Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers, 47(3):225-241.
5. Zhang ZY (1998). Protein-tyrosine phosphatases: biological function, structural characteristics, and mechanism of catalysis. Crit. Rev. Biochem. Mol. Biol., 33(1):1-52.
6. Haase H, Maret W (2005). Protein tyrosine phosphatases as targets of the combined insulinomimetic effects of zinc and oxidants. BioMetals, 18:333–338.
7. Mustelin T, Vang T, Bottini N (2005). Protein tyrosine phosphatases and the immune response. Nat. Rev. Immunol., 5(1):43-57.
Neuropeptide W-30
Discovery
NPW human gene has been identified by Tanaka et al., (2003), who also cloned the mouse Neuropeptide W gene and reported restricted expression in specific neurons in the midbrain and brainstem. Shimomura et al., (2002) identified Neuropeptide W-23 and NPW-30. Brezillon et al., (2003) reported that NPW is expressed in substantia nigra, lymphoblastic leukemia, fetal kidney, colorectal adenocarcinoma, and trachea. Kitamura et al., (2006) and Jackson et al., (2006) localized expression of NPW in various areas of the rat Brain. Takenoya et al., (2008) reported that neuropeptide W is found in neurons also expressing orexin and melanin concentrating hormone. Hochol et al.,(2006) reported the expression of NPW and its receptors in hypothalamus, anterior pituitary, thyroid and parathyroid glands, pancreatic islets, adrenal glands, ovary and testis of the rat 1-8.
Structural Characteristics
NPW is a neuropeptide hormone of 30 amino acids derived from a prepro-protein of 165 amino acids (termed PPNPW) 3.
Mode of Action
The receptors for neuropeptide W have been identified in humans as the G-protein-coupled receptors GRP7 [G-protein-coupled receptor-7] and GPR8 [G-protein-coupled receptor-8] . The short form of neuropeptide W is the most potent receptor agonist 1-3. GPR8 receptors are absent in rodents, where the GPR8-LR [GPR8-like receptor] has been described9. Receptors have been shown to be expressed in neurons in various brain areas10, adrenocortical cells. Rat adrenocortical cells produce Neuropeptide W and also express the receptor, suggesting autocrine and/or paracrine acivities 7.
Functions
Hochol et al., (2006) have suggested a role of NPW in the autocrine and/or paracrine functional regulation of the endocrine system in the rat. Intraperitoneal of NPW raises plasma levels of parathyroid hormone, corticosterone and testosterone, ACTH and estradiol. NPW enhances ACTH stimulated aldosterone secretion from adrenocortical cells and does not affect either basal or ACTH stimulated corticosterone production. Prolonged exposure to NPW raises corticosterone secretion and increases the proliferation rate of cultured cells 7, 8. Endogenous NPW may play a physiologically relevant role in the neuroendocrine response to stress that may modulate the hypothalamic-pituitary-adrenocortical axis. NPW has been reported to elevate prolactin and corticosterone and lowering growth hormone levels in the circulation. However, as shown by in vitro stimulation of dispersed anterior pituitary cells, it does not itself act as a true releasing or inhibiting factor in the anterior pituitary gland. The central effects of NPW to inhibit growth hormone release result from activation of arcuate somatostatin neurons, which could result in an inhibition of neurons expressing growth hormone releasing hormone. Centrally administered NP W-30 activates magnocellular neurosecretory cells in the supraoptic and paraventricular nuclei and significantly increases plasma arginine-vasopressin and plasma oxytocin levels.
NPW acts as an endogenous catabolic signaling molecule in the brain. Injection of NPW into paraventricular nucleus of hypothalamus increases food intake. Both forms of neuropeptide W suppress dark phase and fasting-induced food intake, and also increase body temperature and heat production. Continuous intracerebroventricular infusion of NPW suppresses feeding and body weight gain, whereas administration of anti-NPW IgG stimulates feeding. NPW is a potent suppressor of blood leptin levels in the rat. It potentiates glucose-induced insulin release and calcium influx in pancreatic beta-cells
Yamamoto et al., (2005) have reported an anti-hyperalgesic effect of intrathecally administered NPW23 in tests of inflammatory pain in rats. Yu et al (2007) have reported cardiovascular activities of NPW30. Intracerebroventricular administration increases the mean arterial pressure, heart rate, and plasma norepinephrine and epinephrine levels. Intravenously administered NPW30 has no significant effects on mean arterial pressure, heart rate 11-22.
References
1. Shimomura Y, Harada M, Goto M, Sugo T, Matsumoto Y, Abe M, Watanabe T, Asami T, Kitada C, Mori M, Onda H, Fujino M.(2002). Identification of Neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem., 277(39):35826-35832.
2. Brezillon S, Lannoy V, Franssen JD, Le Poul E, Dupriez V, Lucchetti J, Detheux M, Parmentier M.(2003). Identification of natural ligands for the orphan G protein-coupled receptors GPR7 and GPR8. J Biol Chem., 278:776-783.
3. Tanaka H, Yoshida T, Miyamoto N, Motoike T, Kurosu H, Shibata K, Yamanaka A, Williams SC, Richardson JA, Tsujino N, Garry MG, Lerner MR, King DS, O'Dowd BF, Sakurai T, Yanagisawa M.(2003). Characterization of a family of endogenous neuropeptide ligands for the G protein-coupled receptors GPR7 and GPR8. PNAS., 100(10):6251-6256.
4. Kitamura Y, Tanaka H, Motoike T, Ishii M, Williams SC, Yanagisawa M, Sakurai T.(2006). Distribution of Neuropeptide W immunoreactivity and mRNA in adult rat brain. Brain Res., 1093(1):123-134.
5. Jackson VR, Lin SH, Wang Z, Nothacker HP, Civelli O. (2006). A study of the rat neuropeptide B/Neuropeptide W system using in situ techniques. J Comp Neurol., 497(3):367-383.
6. Takenoya F, Kitamura S, Kageyama H, Nonaka N, Seki M, Itabashi K, Date Y, Nakazato M, Shioda S (2008). Neuronal interactions between Neuropeptide W- and orexin- or melanin-concentrating hormone-containing neurons in the rat hypothalamus. Regul Pep., 145(1-3):159-164.
7. Hochol A, Albertin G, Nussdorfer GG, Spinazzi R, Ziolkowska A, Rucinski M, Malendowicz LK.(2004). Effects of neuropeptides B and W on the secretion and growth of rat adrenocortical cells. Intl J Mol Med.,14(5): 843-847 (2004);
8. Hochol A, Belloni AS, Rucinski M, Ziolkowska A, Di Liddo R, Nussdorfer GG, Malendowicz LK. (2006). Expression of neuropeptides B and W and their receptors in endocrine glands of the rat. Int J Mol Med., 18(6):1101-1106.
9. Lee DK, Nguyen T, Porter CA, Cheng R, George SR, O'Dowd BF. (1999). Two related G protein-coupled receptors: the distribution of GPR7 in rat brain and the absence of GPR8 in rodents. Brain Res Mol Brain Res., 71(1):96-103.
10. Singh G, Maguire JJ, Kuc RE, Fidock M, Davenport AP.(2004). Identification and cellular localisation of NPW1 (GPR7) receptors for the novel Neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry. Brain Res., 1017(1-2):222-226.
11. Taylor MM, Yuill EA, Baker JR, Ferri CC, Ferguson AV, Samson WK. (2005). Actions of Neuropeptide W in paraventricular hypothalamus: implications for the control of stress hormone secretion. Am J Physiol Regul Integr Comp Physiol 288(1): 270-275.
12. Niimi M and Murao K. 2005. Neuropeptide W as a stress mediator in the hypothalamus. Endocrine., 27(1): 51-54.
13. Baker JR, Cardinal K, Bober C, Taylor MM, Samson WK. (2003). Neuropeptide W acts in brain to control prolactin, corticosterone, and growth hormone release. Endocrinology., 144(7):2816-2821.
14. Price CJ, Samson WK, Ferguson AV. (2008). Neuropeptide W influences the excitability of neurons in the rat hypothalamic arcuate nucleus. Neuroendocrinology., 88(2):88-94.
15. Kawasaki M, Onaka T, Nakazato M, Saito J, Mera T, Hashimoto H, Fujihara H, Okimoto N, Ohnishi H, Nakamura T, Ueta Y. (2006). Centrally administered Neuropeptide W-30 activates magnocellular neurosecretory cells in the supraoptic and paraventricular nuclei with neurosecretion in rats. J Endocrinol., 190(2):213-223.
16. Dezaki K, Kageyama H, Seki M, Shioda S, Yada T.(2008). Neuropeptide W in the rat pancreas: potentiation of glucose-induced insulin release and Ca2+ influx through L-type Ca2+ channels in beta-cells and localization in islets. Regul Pep., 145(1-3):153-158.
17. Levine AS, Winsky-Sommerer R, Huitron-Resendiz S, Grace MK, de Lecea L.(2005). Injection of Neuropeptide W into paraventricular nucleus of hypothalamus increases food intake. Am J Physiol Regul Integr Comp Physiol., 288(6):1727-1732.
18. Mazzocchi G, Rebuffat P, Ziolkowska A, Rossi GP, Malendowicz LK, Nussdorfer GG.(2005). G protein receptors 7 and 8 are expressed in human adrenocortical cells, and their endogenous ligands neuropeptides B and w enhance cortisol secretion by activating adenylate cyclase- and phospholipase C-dependent signaling cascades. J Clin Endocrinol Metab., 90(6):3466-3471.
19. Mondal MS, Yamaguchi H, Date Y, Shimbara T, Toshinai K, Shimomura Y, Mori M, Nakazato M.(2003). A role for Neuropeptide W in the regulation of feeding behavior. Endocrinology., 144(11):4729-4733.
20. Rucinski M, Nowak KW, Chmielewska J, Ziolkowska A, Malendowicz LK.( 2007). Neuropeptide W exerts a potent suppressive effect on blood leptin and insulin concentrations in the rat. Int J Mol Med., 19(3):401-405.
21. Yamamoto T, Saito O, Shono K, Tanabe S.(2005). Anti-hyperalgesic effects of intrathecally administered Neuropeptide W-23, and neuropeptide B, in tests of inflammatory pain in rats. Brain Res., 1045(1-2):97-106.
22. Yu N, Chu C, Kunitake T, Kato K, Nakazato M, Kannan H.(2007). Cardiovascular actions of central Neuropeptide W in conscious rats. Regul Pep., 138(2-3):82-86.
NPW human gene has been identified by Tanaka et al., (2003), who also cloned the mouse Neuropeptide W gene and reported restricted expression in specific neurons in the midbrain and brainstem. Shimomura et al., (2002) identified Neuropeptide W-23 and NPW-30. Brezillon et al., (2003) reported that NPW is expressed in substantia nigra, lymphoblastic leukemia, fetal kidney, colorectal adenocarcinoma, and trachea. Kitamura et al., (2006) and Jackson et al., (2006) localized expression of NPW in various areas of the rat Brain. Takenoya et al., (2008) reported that neuropeptide W is found in neurons also expressing orexin and melanin concentrating hormone. Hochol et al.,(2006) reported the expression of NPW and its receptors in hypothalamus, anterior pituitary, thyroid and parathyroid glands, pancreatic islets, adrenal glands, ovary and testis of the rat 1-8.
Structural Characteristics
NPW is a neuropeptide hormone of 30 amino acids derived from a prepro-protein of 165 amino acids (termed PPNPW) 3.
Mode of Action
The receptors for neuropeptide W have been identified in humans as the G-protein-coupled receptors GRP7 [G-protein-coupled receptor-7] and GPR8 [G-protein-coupled receptor-8] . The short form of neuropeptide W is the most potent receptor agonist 1-3. GPR8 receptors are absent in rodents, where the GPR8-LR [GPR8-like receptor] has been described9. Receptors have been shown to be expressed in neurons in various brain areas10, adrenocortical cells. Rat adrenocortical cells produce Neuropeptide W and also express the receptor, suggesting autocrine and/or paracrine acivities 7.
Functions
Hochol et al., (2006) have suggested a role of NPW in the autocrine and/or paracrine functional regulation of the endocrine system in the rat. Intraperitoneal of NPW raises plasma levels of parathyroid hormone, corticosterone and testosterone, ACTH and estradiol. NPW enhances ACTH stimulated aldosterone secretion from adrenocortical cells and does not affect either basal or ACTH stimulated corticosterone production. Prolonged exposure to NPW raises corticosterone secretion and increases the proliferation rate of cultured cells 7, 8. Endogenous NPW may play a physiologically relevant role in the neuroendocrine response to stress that may modulate the hypothalamic-pituitary-adrenocortical axis. NPW has been reported to elevate prolactin and corticosterone and lowering growth hormone levels in the circulation. However, as shown by in vitro stimulation of dispersed anterior pituitary cells, it does not itself act as a true releasing or inhibiting factor in the anterior pituitary gland. The central effects of NPW to inhibit growth hormone release result from activation of arcuate somatostatin neurons, which could result in an inhibition of neurons expressing growth hormone releasing hormone. Centrally administered NP W-30 activates magnocellular neurosecretory cells in the supraoptic and paraventricular nuclei and significantly increases plasma arginine-vasopressin and plasma oxytocin levels.
NPW acts as an endogenous catabolic signaling molecule in the brain. Injection of NPW into paraventricular nucleus of hypothalamus increases food intake. Both forms of neuropeptide W suppress dark phase and fasting-induced food intake, and also increase body temperature and heat production. Continuous intracerebroventricular infusion of NPW suppresses feeding and body weight gain, whereas administration of anti-NPW IgG stimulates feeding. NPW is a potent suppressor of blood leptin levels in the rat. It potentiates glucose-induced insulin release and calcium influx in pancreatic beta-cells
Yamamoto et al., (2005) have reported an anti-hyperalgesic effect of intrathecally administered NPW23 in tests of inflammatory pain in rats. Yu et al (2007) have reported cardiovascular activities of NPW30. Intracerebroventricular administration increases the mean arterial pressure, heart rate, and plasma norepinephrine and epinephrine levels. Intravenously administered NPW30 has no significant effects on mean arterial pressure, heart rate 11-22.
References
1. Shimomura Y, Harada M, Goto M, Sugo T, Matsumoto Y, Abe M, Watanabe T, Asami T, Kitada C, Mori M, Onda H, Fujino M.(2002). Identification of Neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem., 277(39):35826-35832.
2. Brezillon S, Lannoy V, Franssen JD, Le Poul E, Dupriez V, Lucchetti J, Detheux M, Parmentier M.(2003). Identification of natural ligands for the orphan G protein-coupled receptors GPR7 and GPR8. J Biol Chem., 278:776-783.
3. Tanaka H, Yoshida T, Miyamoto N, Motoike T, Kurosu H, Shibata K, Yamanaka A, Williams SC, Richardson JA, Tsujino N, Garry MG, Lerner MR, King DS, O'Dowd BF, Sakurai T, Yanagisawa M.(2003). Characterization of a family of endogenous neuropeptide ligands for the G protein-coupled receptors GPR7 and GPR8. PNAS., 100(10):6251-6256.
4. Kitamura Y, Tanaka H, Motoike T, Ishii M, Williams SC, Yanagisawa M, Sakurai T.(2006). Distribution of Neuropeptide W immunoreactivity and mRNA in adult rat brain. Brain Res., 1093(1):123-134.
5. Jackson VR, Lin SH, Wang Z, Nothacker HP, Civelli O. (2006). A study of the rat neuropeptide B/Neuropeptide W system using in situ techniques. J Comp Neurol., 497(3):367-383.
6. Takenoya F, Kitamura S, Kageyama H, Nonaka N, Seki M, Itabashi K, Date Y, Nakazato M, Shioda S (2008). Neuronal interactions between Neuropeptide W- and orexin- or melanin-concentrating hormone-containing neurons in the rat hypothalamus. Regul Pep., 145(1-3):159-164.
7. Hochol A, Albertin G, Nussdorfer GG, Spinazzi R, Ziolkowska A, Rucinski M, Malendowicz LK.(2004). Effects of neuropeptides B and W on the secretion and growth of rat adrenocortical cells. Intl J Mol Med.,14(5): 843-847 (2004);
8. Hochol A, Belloni AS, Rucinski M, Ziolkowska A, Di Liddo R, Nussdorfer GG, Malendowicz LK. (2006). Expression of neuropeptides B and W and their receptors in endocrine glands of the rat. Int J Mol Med., 18(6):1101-1106.
9. Lee DK, Nguyen T, Porter CA, Cheng R, George SR, O'Dowd BF. (1999). Two related G protein-coupled receptors: the distribution of GPR7 in rat brain and the absence of GPR8 in rodents. Brain Res Mol Brain Res., 71(1):96-103.
10. Singh G, Maguire JJ, Kuc RE, Fidock M, Davenport AP.(2004). Identification and cellular localisation of NPW1 (GPR7) receptors for the novel Neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry. Brain Res., 1017(1-2):222-226.
11. Taylor MM, Yuill EA, Baker JR, Ferri CC, Ferguson AV, Samson WK. (2005). Actions of Neuropeptide W in paraventricular hypothalamus: implications for the control of stress hormone secretion. Am J Physiol Regul Integr Comp Physiol 288(1): 270-275.
12. Niimi M and Murao K. 2005. Neuropeptide W as a stress mediator in the hypothalamus. Endocrine., 27(1): 51-54.
13. Baker JR, Cardinal K, Bober C, Taylor MM, Samson WK. (2003). Neuropeptide W acts in brain to control prolactin, corticosterone, and growth hormone release. Endocrinology., 144(7):2816-2821.
14. Price CJ, Samson WK, Ferguson AV. (2008). Neuropeptide W influences the excitability of neurons in the rat hypothalamic arcuate nucleus. Neuroendocrinology., 88(2):88-94.
15. Kawasaki M, Onaka T, Nakazato M, Saito J, Mera T, Hashimoto H, Fujihara H, Okimoto N, Ohnishi H, Nakamura T, Ueta Y. (2006). Centrally administered Neuropeptide W-30 activates magnocellular neurosecretory cells in the supraoptic and paraventricular nuclei with neurosecretion in rats. J Endocrinol., 190(2):213-223.
16. Dezaki K, Kageyama H, Seki M, Shioda S, Yada T.(2008). Neuropeptide W in the rat pancreas: potentiation of glucose-induced insulin release and Ca2+ influx through L-type Ca2+ channels in beta-cells and localization in islets. Regul Pep., 145(1-3):153-158.
17. Levine AS, Winsky-Sommerer R, Huitron-Resendiz S, Grace MK, de Lecea L.(2005). Injection of Neuropeptide W into paraventricular nucleus of hypothalamus increases food intake. Am J Physiol Regul Integr Comp Physiol., 288(6):1727-1732.
18. Mazzocchi G, Rebuffat P, Ziolkowska A, Rossi GP, Malendowicz LK, Nussdorfer GG.(2005). G protein receptors 7 and 8 are expressed in human adrenocortical cells, and their endogenous ligands neuropeptides B and w enhance cortisol secretion by activating adenylate cyclase- and phospholipase C-dependent signaling cascades. J Clin Endocrinol Metab., 90(6):3466-3471.
19. Mondal MS, Yamaguchi H, Date Y, Shimbara T, Toshinai K, Shimomura Y, Mori M, Nakazato M.(2003). A role for Neuropeptide W in the regulation of feeding behavior. Endocrinology., 144(11):4729-4733.
20. Rucinski M, Nowak KW, Chmielewska J, Ziolkowska A, Malendowicz LK.( 2007). Neuropeptide W exerts a potent suppressive effect on blood leptin and insulin concentrations in the rat. Int J Mol Med., 19(3):401-405.
21. Yamamoto T, Saito O, Shono K, Tanabe S.(2005). Anti-hyperalgesic effects of intrathecally administered Neuropeptide W-23, and neuropeptide B, in tests of inflammatory pain in rats. Brain Res., 1045(1-2):97-106.
22. Yu N, Chu C, Kunitake T, Kato K, Nakazato M, Kannan H.(2007). Cardiovascular actions of central Neuropeptide W in conscious rats. Regul Pep., 138(2-3):82-86.
Enterostatins
Definition
Enterostatin is a pentapeptide generated by the action of trypsin on procolipase in the intestinal lumen. Pharmacologic studies have suggested a role for these peptides in appetite regulation and insulin secretion 1.
Related Peptides
Enterostatins belong to a family of peptides (e.g., Val-Pro-Asp-Pro-Arg, VPDPR; Ala-Pro-Gly-Pro-Arg, APGPR; and Val-Pro-Gly-Pro-Arg, VPGPR) derived from the tryptic cleavage of amino-terminal pentapeptide from procolipase 1.
Discovery
In 1993, Mei et al., identified the peptapeptide obtained from the tryptic cleavage of the N-terminal of procolipase and named it enterostatin 2.
Structural Characteristics
Enterostatin structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference 3. Modifications in the N-terminus of VPDPR abrogate biological function, other modifications result in retention of biological activity. The importance of the N-terminal residue of enterostatin was investigated by replacing the L-valine with (i) D-valine, (ii) L-tyrosine or (iii) addition of an L-tyrosine to generate the hexapeptide, YVPDPR. Replacement of the N-terminal L-valine residue with D-valine abrogated the insulin inhibitory activity of the peptide. This demonstrates that the N-terminal valine may be necessary for biological function and is consistent with a previous report showing a lack of effect of D-VPDPR on high-fat food consumption 4.
Mode of Action
A high-fat diet easily promotes hyperphagia giving an impression of an uncontrolled process. Fat digestion itself however provides control of fat intake through the digestion, carried out by pancreatic lipase and its protein cofactor colipase, and through enterostatin, released from procolipase during fat digestion 5. Neural mechanisms arising from the intestine involving vagal afferent nerves may be important for the early satiety mechanism induced by enterostatin during a meal 6. Enterostatin acts through an opioid pathway, rather as a µ-antagonist acting antagonistic to ß-casomorphin. In its mechanism of action enterostatin gives an exothermic reaction, while the opiate has an endothermic reaction. The decreased thermogenesis by opiates could explain an increased appetite and body weight, while an increased thermogenesis by enterostatin could explain a reduction in appetite and loss of body weight. The hypocholesterolemic effects of APGPR and VPDPR are mediated by a CCK1 receptor-dependent mechanism 7.
Functions
Enterostatin released from the exocrine pancreas and gastrointestinal tract, selectively inhibits fat intake through activation of an afferent vagal signaling pathway 8. Recent studies indicate that enterostatin modulates insulin release in response to a variety of agents that affect first phase as well as the second phase of insulin release 4.
References
1. Imamura M, Sumar N, Hermon-Taylor J, Robertson HJ, Prasad C (1998). Distribution and characterization of enterostatin-like immunoreactivity in human cerebrospinal fluid. Peptides, 19(8):1385-1391.
2. Mei J, Bowyer RC, Jehanli AMT, Patel G, Erlanson-Albertsson C (1993). Identification of enterostatin, the pancreatic procolipase activation peptide in the intestine of rat. Pancreas, 8:488-493.
3. Prasad C, Imamura M, Debata C, Svec F, Sumar N, Hermon-Taylor J (1999). Hyper- enterostatinemia in Premenopausal Obese Women. J Clin Endocrinol Metab., 84(3):937-941.
4. Tadayyon M, Liou S, Briscoe CP, Badman G, Eggleston DS, Arch JRS, York DA (2002). Structure-function studies on enterostatin inhibition of insulin release. Int J Diabetes & Metabolism., 10:14-21.
5. Berger K, Winzell MS, Mei J, Erlanson-Albertsson C (2004). Enterostatin and its target mechanisms during regulation of fat intake. Physiol Behav., 83(4):623-630.
6. Mei J, Sörhede-Winzell M, Erlanson-Albertsson C (2002). Plasma Enterostatin: Identification and Release in Rats in Response to a Meal. Obes Res., 10(7):688–694.
7. Takenaka Y, Shimano T, Mori T, Hou IC, Ohinata K, Yoshikawa M. (2008). Enterostatin reduces serum cholesterol levels by way of a CCK1 receptor-dependent mechanism. Peptides.,29(12):2175-2178.
8. Lin L, Thomas SR, Kilroy G, Schwartz GJ, York DA (2003). Enterostatin inhibition of dietary fat intake is dependent on CCK-A receptors Am J Physiol Regul Integr Comp Physiol., 285(2):321-328.
Enterostatin is a pentapeptide generated by the action of trypsin on procolipase in the intestinal lumen. Pharmacologic studies have suggested a role for these peptides in appetite regulation and insulin secretion 1.
Related Peptides
Enterostatins belong to a family of peptides (e.g., Val-Pro-Asp-Pro-Arg, VPDPR; Ala-Pro-Gly-Pro-Arg, APGPR; and Val-Pro-Gly-Pro-Arg, VPGPR) derived from the tryptic cleavage of amino-terminal pentapeptide from procolipase 1.
Discovery
In 1993, Mei et al., identified the peptapeptide obtained from the tryptic cleavage of the N-terminal of procolipase and named it enterostatin 2.
Structural Characteristics
Enterostatin structure is highly conserved in evolution, with an amino acid sequence of XPXPR. Three enterostatin sequences, Val-Pro-Asp-Pro-Arg (VPDPR), Val-Pro-Gly-Pro-Arg (VPGPR), and Ala-Pro-Gly-Pro-Arg (APGPR), have been studied extensively and shown to be almost equally effective in their ability to decrease dietary fat preference 3. Modifications in the N-terminus of VPDPR abrogate biological function, other modifications result in retention of biological activity. The importance of the N-terminal residue of enterostatin was investigated by replacing the L-valine with (i) D-valine, (ii) L-tyrosine or (iii) addition of an L-tyrosine to generate the hexapeptide, YVPDPR. Replacement of the N-terminal L-valine residue with D-valine abrogated the insulin inhibitory activity of the peptide. This demonstrates that the N-terminal valine may be necessary for biological function and is consistent with a previous report showing a lack of effect of D-VPDPR on high-fat food consumption 4.
Mode of Action
A high-fat diet easily promotes hyperphagia giving an impression of an uncontrolled process. Fat digestion itself however provides control of fat intake through the digestion, carried out by pancreatic lipase and its protein cofactor colipase, and through enterostatin, released from procolipase during fat digestion 5. Neural mechanisms arising from the intestine involving vagal afferent nerves may be important for the early satiety mechanism induced by enterostatin during a meal 6. Enterostatin acts through an opioid pathway, rather as a µ-antagonist acting antagonistic to ß-casomorphin. In its mechanism of action enterostatin gives an exothermic reaction, while the opiate has an endothermic reaction. The decreased thermogenesis by opiates could explain an increased appetite and body weight, while an increased thermogenesis by enterostatin could explain a reduction in appetite and loss of body weight. The hypocholesterolemic effects of APGPR and VPDPR are mediated by a CCK1 receptor-dependent mechanism 7.
Functions
Enterostatin released from the exocrine pancreas and gastrointestinal tract, selectively inhibits fat intake through activation of an afferent vagal signaling pathway 8. Recent studies indicate that enterostatin modulates insulin release in response to a variety of agents that affect first phase as well as the second phase of insulin release 4.
References
1. Imamura M, Sumar N, Hermon-Taylor J, Robertson HJ, Prasad C (1998). Distribution and characterization of enterostatin-like immunoreactivity in human cerebrospinal fluid. Peptides, 19(8):1385-1391.
2. Mei J, Bowyer RC, Jehanli AMT, Patel G, Erlanson-Albertsson C (1993). Identification of enterostatin, the pancreatic procolipase activation peptide in the intestine of rat. Pancreas, 8:488-493.
3. Prasad C, Imamura M, Debata C, Svec F, Sumar N, Hermon-Taylor J (1999). Hyper- enterostatinemia in Premenopausal Obese Women. J Clin Endocrinol Metab., 84(3):937-941.
4. Tadayyon M, Liou S, Briscoe CP, Badman G, Eggleston DS, Arch JRS, York DA (2002). Structure-function studies on enterostatin inhibition of insulin release. Int J Diabetes & Metabolism., 10:14-21.
5. Berger K, Winzell MS, Mei J, Erlanson-Albertsson C (2004). Enterostatin and its target mechanisms during regulation of fat intake. Physiol Behav., 83(4):623-630.
6. Mei J, Sörhede-Winzell M, Erlanson-Albertsson C (2002). Plasma Enterostatin: Identification and Release in Rats in Response to a Meal. Obes Res., 10(7):688–694.
7. Takenaka Y, Shimano T, Mori T, Hou IC, Ohinata K, Yoshikawa M. (2008). Enterostatin reduces serum cholesterol levels by way of a CCK1 receptor-dependent mechanism. Peptides.,29(12):2175-2178.
8. Lin L, Thomas SR, Kilroy G, Schwartz GJ, York DA (2003). Enterostatin inhibition of dietary fat intake is dependent on CCK-A receptors Am J Physiol Regul Integr Comp Physiol., 285(2):321-328.
Endothelins and Related Peptides
Definition
A peptidergic activity produced in endothelial cells that caused coronary vasoconstriction was described in 1985, and a family of peptides, named the endothelins, was subsequently isolated and identified. The three members of the family — endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3 )— are produced in a variety of tissues, where they act as modulators of vasomotor tone, cell proliferation, and hormone production 1.
Related Peptides
The 21-amino acid peptide ET-1 is the predominant isoform of the endothelin peptide family, which includes ET-2, ET-3, and ET-4. It exerts various biological effects, including vasoconstriction and the stimulation of cell proliferation in tissues both within and outside of the cardiovascular system. ET-1 is synthesized by endothelin-converting enzymes (ECE), chymases, and non-ECE metalloproteases; it is regulated in an autocrine fashion in vascular and nonvascular cells 2.
Discovery
Endothelin, one of the most potent vasoconstrictors, was first discovered by Yanagisawa and co-workers in 1981. It was first isolated, characterized, and cloned in porcine aortic endothelial cells 3.
Structural Characteristics
First of the three isoforms, the ET-1, is a 21-amino acid peptide; it has a molecular weight of 2,492, free carboxyl and amino termini and has two intramolecular disulfide bonds. It is present in many mammalian species, including humans. Other two human endothelin isopeptides, ET-2 and ET-3 are encoded by separate genes. They contain two intramolecular disulfide bonds. They also contain a cluster of polar charged side chains in the hairpin loop and a hydrophobic COOH terminus, containing the aromatic indole side chain at trp21 3.
Mode of Action
Two endothelin receptors have been characterised in the mammals. They are classified according to the relative binding affinities of the 3-endothelin isopeptides to the receptors. The order of affinity of endothelins for 1st receptor type designated ETA is ET-1 > ET-2 > ET- 3. The second receptor subtype designated ETB shows equipotent affinity for all 3 endothelins 3.
Functions
Endothelins appear to act mainly as local paracrine/autocrine peptides, but circulating levels of endothelins also have great biological significance especially in pathological states of increased serum concentration.
Pathophysiology of Endothelins:
1. Renal haemodynamics: In various studies in dogs and rats it has been seen that endothelin peptides have both contractile and promitogenic actions in renal mesangial cells.
2. Renal disease: In various studies it has been shown that ET-1 plays a role in the pathogenesis of acute renal failure after renal ischaemia, i.e., plasma levels of ET-1 are increased in patients with acute renal failure.
3. Hypertension: ET-1 causes potent vasoconstriction and prolonged elevation of blood pressure in experimental models. But the relationship between the plasma levels of ET-1 and severity of hypertension is inconsistent in humans.
4. Heart failure: Plasma endothelin levels are increased in animal models of CHF (Chronic Heart Failure) and in patients with CHF. In patients, increased plasma endothelin levels correlate closely with the degree of haemodynamic and functional impairment, with higher levels predicting a greater likelihood of death or need for cardiac transplantation.
5. Ischaemic heart disease: In human studies, plasma endothelin levels are increased in unstable angina and acute myocardial infarction.
6. Variant angina: Patients with Prinzmetal’s angina are known to have endothelial dysfunction affecting the L-arginine nitric oxide system, and as a potent vasoconstrictor of coronary arteries, endothelin-1 has been implicated in the pathophysiology of this condition.
7. Primary pulmonary hypertension: In primary pulmonary hypertension there is proliferation of pulmonary arterial smooth muscle and endothelial injury. It has been observed that depending on the state of vasomotor tone, endothelin isopeptides can cause either pulmonary vasodilatation or vasoconstriction.
8. Raynaud’s disease: Raynaud’s disease is seen commonly in cold climates and is associated with vasospastic conditions like migraine and Prinzmetal’s angina. There has been exaggerated increase in endothelin levels in venous blood draining from the cold challenged arm, in cases with Raynaud’s disease as compared with responses in healthy volunteers.
9. Subarachnoid haemorrhage (SAH): Endothelin-1 has a causative role in mediating sub-arachnoid hemorrhage induced vasospasm. Plasma and CSF endothelin levels are significantly increased in patients after SAH and plasma levels of endothelins are highest in those who develop vasospasm.
10. Migraine: In the recent studies it has been found that levels of endothelins are increased during migraine headaches 3.
References
1. Levin ER (1995). Endothelins. NEJM., 333:356-363.
2. Lüscher TF, Barton M (2000). Endothelins and Endothelin Receptor Antagonists Circulation., 102:2434:2440.
3. Jain SK, Yadava RK, Raikar R (2002). Role of Endothelins in Health and Disease. JIACM, 3(1):59-64
A peptidergic activity produced in endothelial cells that caused coronary vasoconstriction was described in 1985, and a family of peptides, named the endothelins, was subsequently isolated and identified. The three members of the family — endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3 )— are produced in a variety of tissues, where they act as modulators of vasomotor tone, cell proliferation, and hormone production 1.
Related Peptides
The 21-amino acid peptide ET-1 is the predominant isoform of the endothelin peptide family, which includes ET-2, ET-3, and ET-4. It exerts various biological effects, including vasoconstriction and the stimulation of cell proliferation in tissues both within and outside of the cardiovascular system. ET-1 is synthesized by endothelin-converting enzymes (ECE), chymases, and non-ECE metalloproteases; it is regulated in an autocrine fashion in vascular and nonvascular cells 2.
Discovery
Endothelin, one of the most potent vasoconstrictors, was first discovered by Yanagisawa and co-workers in 1981. It was first isolated, characterized, and cloned in porcine aortic endothelial cells 3.
Structural Characteristics
First of the three isoforms, the ET-1, is a 21-amino acid peptide; it has a molecular weight of 2,492, free carboxyl and amino termini and has two intramolecular disulfide bonds. It is present in many mammalian species, including humans. Other two human endothelin isopeptides, ET-2 and ET-3 are encoded by separate genes. They contain two intramolecular disulfide bonds. They also contain a cluster of polar charged side chains in the hairpin loop and a hydrophobic COOH terminus, containing the aromatic indole side chain at trp21 3.
Mode of Action
Two endothelin receptors have been characterised in the mammals. They are classified according to the relative binding affinities of the 3-endothelin isopeptides to the receptors. The order of affinity of endothelins for 1st receptor type designated ETA is ET-1 > ET-2 > ET- 3. The second receptor subtype designated ETB shows equipotent affinity for all 3 endothelins 3.
Functions
Endothelins appear to act mainly as local paracrine/autocrine peptides, but circulating levels of endothelins also have great biological significance especially in pathological states of increased serum concentration.
Pathophysiology of Endothelins:
1. Renal haemodynamics: In various studies in dogs and rats it has been seen that endothelin peptides have both contractile and promitogenic actions in renal mesangial cells.
2. Renal disease: In various studies it has been shown that ET-1 plays a role in the pathogenesis of acute renal failure after renal ischaemia, i.e., plasma levels of ET-1 are increased in patients with acute renal failure.
3. Hypertension: ET-1 causes potent vasoconstriction and prolonged elevation of blood pressure in experimental models. But the relationship between the plasma levels of ET-1 and severity of hypertension is inconsistent in humans.
4. Heart failure: Plasma endothelin levels are increased in animal models of CHF (Chronic Heart Failure) and in patients with CHF. In patients, increased plasma endothelin levels correlate closely with the degree of haemodynamic and functional impairment, with higher levels predicting a greater likelihood of death or need for cardiac transplantation.
5. Ischaemic heart disease: In human studies, plasma endothelin levels are increased in unstable angina and acute myocardial infarction.
6. Variant angina: Patients with Prinzmetal’s angina are known to have endothelial dysfunction affecting the L-arginine nitric oxide system, and as a potent vasoconstrictor of coronary arteries, endothelin-1 has been implicated in the pathophysiology of this condition.
7. Primary pulmonary hypertension: In primary pulmonary hypertension there is proliferation of pulmonary arterial smooth muscle and endothelial injury. It has been observed that depending on the state of vasomotor tone, endothelin isopeptides can cause either pulmonary vasodilatation or vasoconstriction.
8. Raynaud’s disease: Raynaud’s disease is seen commonly in cold climates and is associated with vasospastic conditions like migraine and Prinzmetal’s angina. There has been exaggerated increase in endothelin levels in venous blood draining from the cold challenged arm, in cases with Raynaud’s disease as compared with responses in healthy volunteers.
9. Subarachnoid haemorrhage (SAH): Endothelin-1 has a causative role in mediating sub-arachnoid hemorrhage induced vasospasm. Plasma and CSF endothelin levels are significantly increased in patients after SAH and plasma levels of endothelins are highest in those who develop vasospasm.
10. Migraine: In the recent studies it has been found that levels of endothelins are increased during migraine headaches 3.
References
1. Levin ER (1995). Endothelins. NEJM., 333:356-363.
2. Lüscher TF, Barton M (2000). Endothelins and Endothelin Receptor Antagonists Circulation., 102:2434:2440.
3. Jain SK, Yadava RK, Raikar R (2002). Role of Endothelins in Health and Disease. JIACM, 3(1):59-64
Subscribe to:
Posts (Atom)